



health

Department:
Health
REPUBLIC OF SOUTH AFRICA

Private Bag X828, PRETORIA, 0001. Civitas Building Cnr Thabo Sehume & Struben Streets, PRETORIA 0001
Directorate: Affordable Medicines, Tel: (012) 395 8530 Fax: (012) 395 8823/4

Enquiries: tenders@health.gov.za

Ref: **HP09-2021SD**

HP09-2021SD: SUPPLY AND DELIVERY OF SOLID DOSAGE FORMS TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 1 MAY 2021 TO 30 APRIL 2023

1. The attached contract circular is for your information.
2. This contract will be subject to the General Conditions of Contract issued in accordance with Chapter 16A of the Treasury Regulations published in terms of the Public Finance Management Act, 1999 (Act 1 of 1999). The Special Requirements and Conditions of Contract are supplementary to the General Conditions of Contract. Where, however, the Special Requirements and Conditions of Contract are in conflict with the General Conditions of the Contract, the Special Requirements and Conditions of Contract will prevail.
3. The bid price offered applies to the product specified e.g. price per single unit, as per specification.
4. The following provincial Departments of Health will participate in this contract:

PARTICIPANTS	CONTACT PERSON	TEL NO	E-MAIL
Eastern Cape	Mr C Dlova	(047) 532-5536	mncedisi.dlova@echealth.gov.za
Free State	Ms M Smits	(051) 411-0525	smitsm@fshealth.gov.za
Gauteng	Mr DS Malele	(011) 628-9131	dumisane.malele@gauteng.gov.za
Kwazulu-Natal	MS SB Nhlapo	(035) 901-7004	sibusisiwe.nhlapo@kznhealth.gov.za
Limpopo	Mr TS Rasekele	(015) 223-9065	rassolly@gmail.com
Mpumalanga	Mr T Moralo	(013) 283-9001	tshegofatsom@mpuhealth.gov.za
North West	Mr M Gutta	(018) 384-4838	mgutta@nwpg.gov.za
Northern Cape	Ms E Delport	(053) 830-2717	edelport@ncpg.gov.za
Western Cape	Mr N Mia	(021) 483-5800	nisaar.mia@westerncape.gov.za

K JAMALOODIEN
DIRECTOR: AFFORDABLE MEDICINES
For: DIRECTOR-GENERAL: HEALTH
DATE: 24 February 2021

(PAGE 2)

1. IMPORTANT GENERAL INFORMATION

- 1.1 Please note that two supplier codes are listed for each supplier. This is to provide for the required supplier registration on the Central Supplier Database (CSD) at National Treasury.
- 1.2 Please note that the delivered price is for the unit of measure (UOM) offered. Unit of Measure, National Stock Numbers and prices should be carefully matched when placing or executing orders.
- 1.3 All prices are inclusive of 15 % VAT.
- 1.4 All prices are on a delivered basis.
- 1.5 Contact persons and e-mail addresses indicated hereunder are to be used for contract enquiries and not for orders.

2. NAMES AND ADDRESSES OF CONTRACTORS AND CONTACT DETAIL

Supplier Name	Supplier Code	CSD Code	Postal Address	Contact Person	Telephone / Cellphone Number	E-mail
Abbott Laboratories South Africa (Pty) Ltd	V2150	MAAA0030395	219 Golf Club Terrace CONSTANTIA KLOOF 1709	Maxine Smith	(011) 858-2379 (060) 579-7944	maxine.smith@abbott.com
Accord Healthcare (Pty) Ltd	V2MB8	MAAA0005335	Private Bag X51 RIVONIA 2128	Reslan Nagoor	(011) 234-5703 (082) 494-2510	reshlan.nagoor@accordhealth.co.za
Adcock Ingram Critical Care (Pty) Ltd	V4222	MAAA0010153	P O Box 6888 JOHANNESBURG 2000	Vusani Matshidza	(011) 494-8129 (079) 894-7873	criticalcare.tenders@adcock.com
Adcock Ingram Healthcare (Pty) Ltd	V2272	MAAA0036413	Private Bag X69 BRYANSTON 2021	Bongani Ngoma	(011) 635-0705 (083) 362-0342	bongani.ngoma@adcock.com

Supplier Name	Supplier Code	CSD Code	Postal Address	Contact Person	Telephone / Cellphone Number	E-mail
Ascendis Pharma (Pty) Ltd	V0DM6	MAAA0043637	Postnet Suite #252 Private Bag X21 BRYANSTON 2021	Marnus Sonnekus	(011) 036-9600 (082) 329-8225	marnus.sonnekus@ascendishealth.com
Aurobindo Pharma (Pty) Ltd	V1MV2	MAAA0039785	P O Box 343 PARKLANDS 2121	Muhammed Omar	(011) 867-9100 (073) 172-7877	muhammed.omar@aurobindo.com
Austell Pharmaceuticals (Pty) Ltd	V1A10	MAAA0034946	1 Sherborne Road PARKTOWN 2193	Irefaan Mahomed	(011) 611-1605 (083) 633-8781	irefaanm@austell.co.za
Bayer (Pty) Ltd	V6390	MAAA0009623	P O Box 143 ISANDO 1600	Magda Noack	(011) 921-5279	za_tenders@bayer.com
Biotech Laboratories (Pty) Ltd	VUV35	MAAA0029826	Private Bag X65 HALFWAY HOUSE 1685	Fariel Dean	(011) 848-3050 (082) 455-1149	tenders@biotechlabs.co.za
Cipla Medpro SA (Pty) Ltd	VXZ32	MAAA0006605	P O Box 1096 DURBANVILLE 7551	Willem Maritz	(011) 315-9150 (082) 887-4926	willem.maritz@cipla.com
Dezzo Trading 392 (Pty) Ltd	V05Y6	MAAA0006141	P O Box 725 LAWLEY 1824	Janet Singh	(011) 036 9600 (076) 053-5148	janet.singh@ascendishealth.com
Dr Reddy's Laboratories (Pty) Ltd	V1A08	MAAA0007549	P O Box 78746 SANDTON 2146	Lorraine Keyser	(011) 324-2100 (082) 826-1823	lorraine@drreddys.com

Supplier Name	Supplier Code	CSD Code	Postal Address	Contact Person	Telephone / Cellphone Number	E-mail
Equity Pharmaceuticals (Pty) Ltd	V1QZ3	MAAA0007480	100 Sovereign Drive Route 21, Corporate Park Nelmapius Drive IRENE 0157	Carel Bouwer	(012) 345-1747 (082) 879-8866	carel@equitypharma.co.za
Evohealth (Pty) Ltd	VFMA4	MAAA0010062	20 Morris Street East Woodmead 703 Office Park WOODMEAD 2191	Jayslen Naidoo	(011) 656-3338 (084) 588-0703	jayslen@vortexhealthcare.co.za
Ferring (Pty) Ltd	VXY92	MAAA0005879	Route 21, Corporate Park 6 Regency Drive IRENE 0157	Martha van Zyl	(012) 443-4307 (082) 565-2656	mvz@ferring.com mercia.vanzyl@ferring.com
Gulf Drug Company (Pty) Ltd	VTS03	MAAA0009791	P O Box 754 MOUNT EDGECOMBE 4302	Kevin Moonsamy	(031) 538-8700 (083) 779-1321	kevinm@gulfdrug.co.za
Innovata Pharmaceuticals (Pty) Ltd	VBBL4	MAAA0003385	P O Box 777 KELVIN 2054	Grace Job	(086) 999-0912 (082) 901-8729	grace@innovata.co.za
Ipharma (Pty) Ltd	V8QU8	MAAA0003048	Postnet 319 Private Bag X1007 LYTTELTON 0140	Natalie Hime	(011) 314-2366 (083) 258-6226	natalie@ipharma.co.za
Janssen Pharmaceutica (Pty) Ltd	VBKY6	MAAA0016328	P O Box 785939 SANDTON 2146	Mark Hood	(011) 518-7152 (082) 416-1244	mhood@its.jnj.com
Litha Pharma (Pty) Ltd (Acino Pharma)	VGS73	MAAA0009244	P O Box 8356 MIDRAND 1685	Dear Anand Reddy	(011) 516-1700 (066) 304-6900	state_za@acino.swiss

Supplier Name	Supplier Code	CSD Code	Postal Address	Contact Person	Telephone / Cellphone Number	E-mail
MSD (Pty) Ltd	V2185	MAAA0077142	Private Bag X3 HALFWAY HOUSE 1685	Harshen Vassan	(011) 655-3157 (072) 652-8951	harshen.vassan@merck.com
Mundipharma (Pty) Ltd	V32G6	MAAA0228483	P O Box 23162 CLAREMONT 7708	Buks Schoeman	(021) 671-5251 (083) 678-8667	buks.schoeman@mundipharma.co.za
Mylan (Pty) Ltd	V3PS6	MAAA0081441	Postnet Suite X23 Private Bag X10010 EDENVALE 1610	Kumaraswamy Ekhambaram	(011) 451-1300 (071) 473-3900	kumaraswamy.ekhambaram@mylan.in
Oethmaan Biosims (Pty) Ltd	V91P2	MAAA0437774	P O Box 421001 FORDSBURG 2033	Muhammad Bodhania	(011) 433-0602 (083) 325-3741	mbodhania@medreich.co.za
Pfizer Laboratories (Pty) Ltd	V2189	MAAA0019202	85 Bute Lane SANDTON 2146	Themba Mnguni	(011) 320-6091 (082) 307-9658	themba.mnguni@pfizer.com
Pharmacare Limited	V2205	MAAA0008452	P O Box 1587 GALLO MANOR 2052	Itumeleng Mathe	(011) 239-6243 (083) 298-4366	imathe@aspenspharma.com
Pharmaco Distribution (Pty) Ltd	VBVW1	MAAA0044115	P O Box 786522 SANDTON 2146	Jan van den Berg	(011) 784-0077 (082) 572-7832	jan.vandenberg@pharmaco.co.za
Pharma-Q (Pty) Ltd	V1NK1	MAAA0016762	Private Bag X09 FLORIDA 1710	Anand Mehta	(011) 247-1600 (083) 636-4444	andy@pharmaq.co.za

Supplier Name	Supplier Code	CSD Code	Postal Address	Contact Person	Telephone / Cellphone Number	E-mail
Ranbaxy Pharmaceuticals (Pty) Ltd	V4728	MAAA0000384	P O Box 43486 INDUSTRIA 2042	Deepakh Sewnarain	(012) 643-2000 (082) 893-8649	deepakh.sewnarain@sunpharma.com
Resmed Healthcare cc	VCEJ2	MAAA0010098	P O Box 65409 RESERVOIR HILLS 4090	Lal Singh	(079) 947-1789	lal@resmed.co.za
Sandoz SA (Pty) Ltd	VVZ69	MAAA0011663	P O Box 12257 VORNA VALLEY 1686	Renee Moodley	(011) 545-0424 (083) 704-1806	renee.moodley@sandoz.com
Sanofi-Aventis SA (Pty) Ltd	V2160	MAAA0009069	Private Bag X207 MIDRAND 1685	Jaidev Maharaj	(011) 847-5264 (082) 943-3952	jaidev.maharaj@sanofi.com
Strides Pharma (Pty) Ltd / Kahma Biotech (Joint Venture)	VB035	MAAA0119416	106 16th Road MIDRAND 1686	Jacques Viljoen	(011) 594-5610 (082) 294-8843	jacques.viljoen@strides.com
Teva Pharmaceuticals (Pty) Ltd	V43G1	MAAA0842904	P O Box 1590 RUIMSIG 1732	Judy Klinkradt	(011) 055-0200 (082) 771-3513	judy.klinkradt@teva.co.za
Trinity Pharma (Pty) Ltd / Kahma Biotech (Joint Venture)	VB035	MAAA0119416	P O Box 68687 BRYANSTON 2021	Marizette Bezuidenhout	(010) 594-5610 (082) 320-0131	marizette@trinitypharma.co.za

Supplier Name	Supplier Code	CSD Code	Postal Address	Contact Person	Telephone / Cellphone Number	E-mail
Unimed Healthcare (Pty) Ltd	V92D6	MAAA0444639	Private Bag X12 PRETORIA WEST 0117	Arshad Bera	(011) 056- 6999 (083) 647-7860	arshad@unimedhealthcare.co.za
Zimbili Pharma cc	VG1E9	MAAA0659559	P O Box 3036 LENASIA 1827	Salmina Mahomed	(011) 852-5252 (082) 603-6575	salmina.mahomed@zimbili.co.za

Item No	Item Specification	Estimate	Quantity Awarded	Split %	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price	Pack Size Offered: Unit Pack	Lead-Time (≤ 14 calendar days)	MOQ	Total Score	National Stock Number	UOM
1	Acetazolamide 250mg tablet, 100 tablets		82 260		Adcock Ingram Healthcare (Pty) Ltd	MAAA0036413	V2272	Azomid tablet 100's	R 63.35	1 x 100	14	50 units per shipper	100.00	189710142	CO
2	Acetazolamide 250mg tablet, 28 tablets		167 750		Adcock Ingram Healthcare (Pty) Ltd	MAAA0036413	V2272	Azomid tablet 30's	R 25.53	1 x 30	14	72 units per shipper	100.00	189752737	CO
3	Acetylcysteine 200mg tablet, 25 tablets Product Awarded: Acetylcysteine 200mg tablet, 20 tablets		18 340		Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Amuco 200	R 40.49	1 x 20	14	5	99.00	222001195	CO
4	Acitretin 10mg capsule, 28 capsules		4 535		Teva Pharmaceuticals (Pty) Ltd	MAAA0842904	V43G1	Neotigason 10 mg	R 728.42	1 x 30	14	2	91.00	180179717	CO
5	Acitretin 25mg capsule, 28 capsules		9 330		Teva Pharmaceuticals (Pty) Ltd	MAAA0842904	V43G1	Neotigason 25 mg	R 1 696.39	1 x 30	14	1	91.00	180179725	CO
8	Alfacalcidol 0,25mcg capsule, 28 capsules		107 030		Adcock Ingram Critical Care (Pty) Ltd	MAAA0010153	V4222	One-Alpha Capsules 0.25UG	R 201.38	1 x 30	14	1	100.00	189712166	CO
9	Alfacalcidol 1mcg capsule, 28 capsules		33 480		Adcock Ingram Critical Care (Pty) Ltd	MAAA0010153	V4222	One-Alpha Capsules 1UG	R 686.55	1 x 30	14	1	100.00	189714139	CO
11	Allopurinol 100mg tablet, 100 tablets		88 270		Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austell Allopurinol 100	R 29.72	1 x 100	14	6	99.00	180105006	CO
12	Allopurinol 100mg tablet, 28 tablets		400 830		Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austell Allopurinol 100	R 9.41	1 x 28	14	10	99.00	181923347	CO
13	Allopurinol 100mg tablet, 56 tablets		162 200		Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austell Allopurinol 100	R 16.60	1 x 56	14	10	99.00	181934797	CO
14	Allopurinol 300mg tablet, 28 tablets	1 130 010	791 007	70%	Adcock Ingram Healthcare (Pty) Ltd	MAAA0036413	V2272	Adco-Allopurinol tablets 300mg 30's	R 17.77	1 x 30	14	50 units per shipper	100.00	180339396	PG
			339 003	30%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austell Allopurinol 300	R 18.59	1 x 30	14	10	94.85		
15	Alprazolam 0,5mg tablet, 30 tablets		35 650		Adcock Ingram Healthcare (Pty) Ltd	MAAA0036413	V2272	Adco-Alzam 0,5mg tablet 30's	R 16.08	1 x 30	14	144 units per shipper	100.00	189714591	CO
17	Amiodarone 200mg tablet, 28 tablets		44 130		Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	BIO-AMIODARONE 200MG TABLETS 30S	R 29.50	1 x 30	14	1	95.00	189710641	CO
18	Amisulpiride 200mg tablet, 28 tablets		198 615		Sanofi-Aventis SA (Pty) Ltd	MAAA0009069	V2160	SOLIAN 200MG TABS 30	R 148.93	1 x 30	14	200	91.00	181807812	CO
19	Amisulpiride 50mg tablet, 28 tablets		62 780		Sanofi-Aventis SA (Pty) Ltd	MAAA0009069	V2160	SOLIAN 50MG TABS 30	R 74.18	1 x 30	14	200	91.00	181807811	CO
20	Amitriptyline 10mg tablet, 100 tablets		74 830		Pharmacare Limited	MAAA0008452	V2205	Trepiline 10mg Tabs 100	R 28.27	1 x 100	14	40	95.00	189710133	CO
21	Amitriptyline 10mg tablet, 28 tablets		1 388 710		Pharmacare Limited	MAAA0008452	V2205	TREPILINE TABS 10MG 28'S BB	R 7.98	1 x 28	14	140	95.00	180339402	PG
22	Amitriptyline 25mg tablet, 100 tablets		125 440		Sandoz SA (Pty) Ltd	MAAA0011663	VVZ69	SANDOZ AMITRIPTYLINE TABS 25 MG 100	R 16.99	1 x 100	14	50	91.00	189760812	BT
23	Amitriptyline 25mg tablet, 168 tablets		11 440		Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	GULF AMITRIPTYLINE 25	R 27.64	1 x 168	14	126	91.00	181917346	CO
24	Amitriptyline 25mg tablet, 28 tablets	4 461 250	4 015 125	90%	Pharmacare Limited	MAAA0008452	V2205	TREPILINE TABS 25MG 28 BB	R 5.08	1 x 28	14	140	95.00	189711829	CO
			446 125	10%	Sandoz SA (Pty) Ltd	MAAA0011663	VVZ69	SANDOZ AMITRIPTYLINE HCl 25 BLISTER 28s	R 6.60	1 x 28	14	50	64.07		
25	Amitriptyline 25mg tablet, 500 tablets		4 750		Pharmacare Limited	MAAA0008452	V2205	TREPILINE 25MG TABS 500'S	R 82.99	1 x 500	14	130	92.22	189710122	CO
26	Amitriptyline 25mg tablet, 56 tablets		446 830		Pharmacare Limited	MAAA0008452	V2205	TREPILINE 25MG TAB 56 BB	R 8.96	1 x 56	14	140	95.00	189711830	CO
27	Amitriptyline 25mg tablet, 84 tablets		221 560		Pharmacare Limited	MAAA0008452	V2205	TREPILINE TABS 25MG 84'S BB	R 13.52	1 x 84	14	140	93.03	189711831	CO
28	Amlodipine 10mg tablet, 28 tablets	17 346 770	4 660 113	26.86%	Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	AMLODIPINE 10 BIOTECH 28 TABLETS	R 4.83	1 x 28	14	100	95.00	181936074	CO
			4 317 041	24.89%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austell Amlodipine 10mg	R 5.42	1 x 28	14	10	88.01		
			4 225 636	24.36%	Cipla Medpro SA (Pty) Ltd	MAAA0006605	VXZ32	Ciplavasc 10	R 5.52	1 x 28	14	720	86.14		
			4 143 981	23.89%	Accord Healthcare (Pty) Ltd	MAAA0005335	V2MB8	Amtas 10mg	R 5.18	1 x 30	14	50	84.48		

Item No	Item Specification	Estimate	Quantity Awarded	Split %	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price	Pack Size Offered: Unit Pack	Lead-Time (≤ 14 calendar days)	MOQ	Total Score	National Stock Number	UOM
29	Amlodipine 5mg tablet, 28 tablets	24 900 580	6 804 206	27.33%	Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	AMLODIPINE 5 BIOTECH 28 TABLETS	R 3.36	1 x 28	14	100	95.00	181936075	CO
			6 222 267	24.99%	Dezzo Trading 392 (Pty) Ltd	MAAA0006141	V05Y6	Amlodipine Ascendis 5	R 3.85	1 x 28	14	100	86.88		
			6 035 535	24.24%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austell Amlodipine 5mg	R 3.91	1 x 28	14	10	84.27		
			5 838 571	23.45%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Amlodipine 5 Unimed	R 4.05	1 x 28	14	300	81.52		
30	Aripiprazole 10mg tablet, 30 tablets		10 510		Sandoz SA (Pty) Ltd	MAAA0011663	VVZ69	ARIZOFY 10mg TAB 30s	R 124.13	1 x 30	14	50	91.00	181807310	CO
31	Aripiprazole 15mg tablet, 30 tablets		5 954		Sandoz SA (Pty) Ltd	MAAA0011663	VVZ69	ARIZOFY 15mg TAB 30s	R 178.11	1 x 30	14	50	91.00	181807313	CO
32	Aripiprazole 5mg tablet, 30 tablets		2 830		Sandoz SA (Pty) Ltd	MAAA0011663	VVZ69	ARIZOFY 5mg TAB 30s	R 98.71	1 x 30	14	50	91.00	181869812	CO
34	Aspirin 300mg scored tablet, 14 tablets	27 306 600	8 984 346	32.90%	Resmed Healthcare cc	MAAA0010098	VCEJ2	Aspirin 300mg Tablets	R 4.97	1 x 14	14	500	79.01	222000916	CO
			7 974 172	29.20%	Ipharma (Pty) Ltd	MAAA0003048	V8QU8	Dr du Toit's Pain Expeller	R 4.92	1 x 14	14	200	70.12		
			10 348 082	37.90%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	GULF ASPIRIN 300mg	R 4.03	1 x 14	14	300	91.00		
35	Aspirin 300mg scored tablet, 96 tablets		481 010		Resmed Healthcare cc	MAAA0010098	VCEJ2	Aspirin 300mg Tablets	R 16.96	1 x 96	14	300	98.87	189714405	CO
36	Atenolol 100mg tablet, 28 tablets		1 171 400		Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	BIO-ATENOLOL 100 TABLETS 28's	R 4.68	1 x 28	14	1	95.00	180192290	PG
37	Atenolol 25mg tablet, 28 tablets		32 400		Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Tenopress 25mg Tablets	R 13.28	1 x 28	14	10	99.00	222001081	CO
38	Atenolol 50mg tablet, 28 tablets	9 002 100	3 293 753	36.59%	Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	BIO-ATENOLOL 50 TABLETS 28's	R 3.36	1 x 28	14	1	95.00	189710125	CO
			3 179 215	35.32%	Dezzo Trading 392 (Pty) Ltd	MAAA0006141	V05Y6	Zetenol 50	R 3.67	1 x 30	14	50	91.70		
			2 529 132	28.09%	Adcock Ingram Healthcare (Pty) Ltd	MAAA0036413	V2272	Adco-Atenolol 50mg tablets 28's	R 4.37	1 x 28	14	72 units per shipper	72.95		
39	Atorvastatin 10mg tablet, 28 tablets	1 157 930	1 042 137	90%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Alipto 10	R 8.91	1 x 28	14	200	100.00	180142176	CO
			115 793	10%	Mylan (Pty) Ltd	MAAA0081441	V3PS6	VASTOR 10 MG	R 11.49	1 x 28	14	100	66.94		
42	Atorvastatin 20mg tablet, 30 tablets		782 810		Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Alipto 20	R 13.64	1 x 30	14	150	100.00	181798133	CO
43	Atorvastatin 40mg tablet, 30 tablets		183 109		Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Alipto 40	R 24.71	1 x 30	14	100	100.00	181859938	CO
44	Baclofen 10mg tablet, 30 tablets		801 250		Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	BIO-BACLOFEN TABLETS 30S	R 17.00	1 x 30	14	1	92.27	189710127	CO
45	Baclofen 25mg tablet, 30 tablets		79 120		Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	BACLOFEN 25 BIOTECH	R 42.95	1 x 30	14	1	95.00	189751273	CO
46	Betamethasone 0,5mg tablet, 20 tablets		5 640		Pharmacare Limited	MAAA0008452	V2205	BETANOID 0.5MG TABS 20'S	R 35.88	1 x 20	14	30	95.00	181801852	CO
47	Betamethasone 0.5mg tablet, 100 tablets		4 278		Pharmacare Limited	MAAA0008452	V2205	BETANOID 0.5MG TABS 100'S	R 152.74	1 x 100	14	30	95.00	222000141	CO
48	Bezafibrate 400mg tablet, 28 tablets		171 540		Sandoz SA (Pty) Ltd	MAAA0011663	VVZ69	Bezafibrate 400mg 30s	R 58.16	1 x 30	14	50	91.00	180000649	CO
51	Biperiden 2mg tablet, 84 tablets Product Awarded: Biperiden 2mg tablet, 100 tablets		189 960		Pharmacare Distribution (Pty) Ltd	MAAA0044115	VBVW1	AKINETON	R 154.65	1 x 100	14	5	90.00	222001082	CO
52	Bisacodyl 5mg enteric coated tablet, 10 tablets		11 200		Pharmacare Limited	MAAA0008452	V2205	Laxador bisacodyl 5mg 10's	R 9.32	1 x 10	14	12	95.00	222001083	CO

Item No	Item Specification	Estimate	Quantity Awarded	Split %	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price	Pack Size Offered: Unit Pack	Lead-Time (≤ 14 calendar days)	MOQ	Total Score	National Stock Number	UOM
53	Bromocriptine 2,5mg tablet, 28 tablets		21 790		Pharmacare Limited	MAAA0008452	V2205	ASPEN BROMOCRIPTINE 2.5MG 30'S	R 61.42	1 x 30	14	50	95.00	189710310	CO
54	Cabergoline 0.5mg tablet, 4 tablets		40 700		Pfizer Laboratories (Pty) Ltd	MAAA0019202	V2189	Dostinex	R 237.37	1 x 4	14	1	91.00	180348494	CO
55	Calcitriol 0,25mcg capsule, 30 capsules		16 304		Pharmaco Distribution (Pty) Ltd	MAAA0044115	VBVW1	ROCALTROL	R 152.00	1 x 30	14	2	90.00	189710186	CO
56	Calcium salt providing 168mg - 240mg elemental calcium, chewable tablet, 168 tablets	2 231 585	1 338 951	60%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	TRI-CAL	R 12.57	1 x 168	14	40	91.00	181860981	PG
			892 634	40%	Evohealth (Pty) Ltd	MAAA0010062	VFMA4	Calcium Chewable 168mg EVO	R 13.90	1 x 168	14	500	90.48		
57	Calcium salt providing 500mg elemental calcium, soluble tablet, 10 tablets	11 575 197	4 183 870	36.15%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Zinplex Calcium 500mg	R 6.34	1 x 10	14	300	100.00	180964704	CO
			3 851 272	33.27%	Evohealth (Pty) Ltd	MAAA0010062	VFMA4	Calcium Soluble 500mg EVO	R 6.90	1 x 10	14	800	92.05		
			3 540 055	30.58%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	FIZZICAL	R 6.79	1 x 10	14	40	84.61		
58	Calcium salt providing 500mg elemental calcium, soluble tablet, 30 tablets	4 328 823	2 597 294	60%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Zinplex Calcium 500mg	R 11.87	1 x 30	14	100	96.21	181917243	CO
			1 731 529	40%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	FIZZICAL	R 11.39	1 x 30	14	100	91.00		
59	Captopril 25mg tablet, 60 tablets		29 330		Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	BIO-CAPTAPRIL 25MG Tablets 60's	R 10.97	1 x 60	14	1	95.00	189710010	CO
60	Carbamazepine 200mg tablet, 100 tablets		148 410		Pharmacare Limited	MAAA0008452	V2205	DEGRANOL 200MG TABS 100'S	R 46.88	1 x 100	14	90	95.00	189710219	CO
61	Carbamazepine 200mg tablet, 28 tablets		1 334 850		Pharmacare Limited	MAAA0008452	V2205	DEGRANOL 200MG TABS 28's	R 15.43	1 x 28	14	100	95.00	181892375	PG
62	Carbamazepine 200mg tablet, 56 tablets	2 160 542	1 512 379	70%	Pharma-Q (Pty) Ltd	MAAA0016762	V1NK1	Zecarb 200	R 28.00	1 x 56	14	70	96.00	180339414	PG
			648 163	30%	Pharmacare Limited	MAAA0008452	V2205	DEGRANOL 200MG TABS 56's	R 29.25	1 x 56	14	100	90.98		
63	Carbamazepine 200mg tablet, 84 tablets	1 730 937	1 384 750	80%	Pharmacare Limited	MAAA0008452	V2205	DEGRANOL TABS 200MG 84'S BB	R 34.66	1 x 84	14	140	95.00	180339437	PG
			346 187	20%	Pharma-Q (Pty) Ltd	MAAA0016762	V1NK1	Zecarb 200	R 39.25	1 x 84	14	50	84.08		
65	Carbidopa 25mg and Levodopa 100mg tablet, 100 tablets		133 800		Ranbaxy Pharmaceuticals (Pty) Ltd	MAAA0000384	V4728	LECARDOP 25/250	R 86.54	1 x 100	14	100	95.00	189710283	CO
66	Carbidopa 25mg and Levodopa 250mg tablet, 100 tablets		31 730		Ranbaxy Pharmaceuticals (Pty) Ltd	MAAA0000384	V4728	LECARDOP 25/100	R 144.84	1 x 100	14	100	95.00	189710383	CO
68	Carvedilol 12.5mg scored tablet, 28 tablets		751 110		Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Carvedilol 12.5 Oethmaan	R 10.35	1 x 28	14	100	90.00	222001084	CO
69	Carvedilol 25mg scored tablet, 28 tablets		1 090 850		Cipla Medpro SA (Pty) Ltd	MAAA0006605	VXZ32	Carloc 25	R 19.78	1 x 30	14	200	99.00	180155487	CO
71	Cetirizine 10mg tablet, 28 tablets	3 284 190	1 970 514	60%	Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	CETIRIZINE 10 BIOTECH	R 3.36	1 x 28	14	100	95.00	222000438	CO
			1 313 676	40%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austell Cetirizine 10 mg	R 3.51	1 x 28	14	10	92.04		
74	Chlorphenamine 4mg tablet, 10 tablets		10 507 150		Adcock Ingram Healthcare (Pty) Ltd	MAAA0036413	V2272	Allergex tablets 10's	R 1.17	1 x 10	14	450 units per shipper	100.00	181821882	PG
75	Chlorphenamine 4mg tablet, 30 tablets		4 505 210		Adcock Ingram Healthcare (Pty) Ltd	MAAA0036413	V2272	Allergex tablets 30's	R 1.90	1 x 30	14	390 units per shipper	100.00	181917348	CO
77	Chlorpromazine 100mg tablet, 56 tablets		171 360		Sanofi-Aventis SA (Pty) Ltd	MAAA0009069	V2160	LARGACTIL 100MG 56 TABS	R 78.90	1 x 56	14	147	91.00	189711826	CO

Item No	Item Specification	Estimate	Quantity Awarded	Split %	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price	Pack Size Offered: Unit Pack	Lead-Time (≤ 14 calendar days)	MOQ	Total Score	National Stock Number	UOM
81	Chlorpromazine 25mg tablet, 56 tablets		120 680		Sanofi-Aventis SA (Pty) Ltd	MAAA0009069	V2160	LARGACTIL 25MG 56 TABS	R 28.75	1 x 56	14	147	91.00	181868872	CO
84	Cinnarizine 25mg tablet, 50 tablets		34 220		Janssen Pharmaceutica (Pty) Ltd	MAAA0016328	VBKY6	Stueroon 25mg	R 69.00	1 x 50	7	1	90.00	189710220	CO
85	Citalopram 10mg tablet, 28 tablets		96 410		Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	BIO CITALOPRAM 10 Tablets 30's	R 6.30	1 x 30	14	1	95.00	222001087	CO
86	Citalopram 20mg tablet, 28 tablets	1 626 000	975 600	60%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Citalopram 20 Oethmaan	R 8.05	1 x 28	14	10	90.00	180129661	CO
			650 400	40%	Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	BIO CITALOPRAM 20 Tablets 30's	R 8.66	1 x 30	14	1	88.18		
87	Clomipramine 25mg tablets, 50 tablets		27 410		Sandoz SA (Pty) Ltd	MAAA0011663	VVZ69	ANAFRANIL TABS 25MG 50	R 103.90	1 x 50	14	50	91.00	181797926	CO
88	Clonazepam 0.5mg tablet, 84 tablets		228 820		Ascendis Pharma (Pty) Ltd	MAAA0043637	V0DM6	Clonam 0,5	R 36.80	1 x 84	14	10	100.00	222001088	CO
89	Clonazepam 2mg tablet, 84 tablets		122 040		Ascendis Pharma (Pty) Ltd	MAAA0043637	V0DM6	Clonam 2	R 86.25	1 x 84	14	10	100.00	222001089	CO
90	Clopidogrel 75mg tablet, 28 tablets		224 030		Trinity Pharma (Pty) Ltd / Kahma Biotech (Joint Venture)	MAAA0119416	VB035	DEPLATT	R 57.44	1 x 30	14	120	92.00	181860507	CO
91	Clozapine 100mg tablet, 100 tablets		179 060		Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Clozapine 100 Oethmaan	R 117.12	1 x 100	14	20	90.00	189710025	CO
92	Clozapine 25mg tablet, 100 tablets		95 220		Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Clozapine 25 Oethmaan	R 36.50	1 x 100	14	20	90.00	189710069	CO
93	Codeine 30mg tablet, 100 tablets		8 575		Pharmacare Limited	MAAA0008452	V2205	CODEINE 30MG TABS 100'S (A-LENNON)	R 452.19	1 x 100	14	20	95.00	189759809	CO
94	Colchicine 0.5mg tablet, 12 tablets		410 020		Pharmacare Limited	MAAA0008452	V2205	COLCHICINE TABS 12'S	R 22.18	1 x 12	14	100	95.00	181937413	CO
95	Danazol 100mg capsule, 60 capsules		3 352		Cipla Medpro SA (Pty) Ltd	MAAA0006605	VXZ32	Danogen-100	R 170.20	1 x 60	14	20	99.00	180280770	CO
98	Desmopressin 0,1mg tablet, 30 tablets		11 950		Ferring (Pty) Ltd	MAAA0005879	VXY92	DDAVP 0.1mg TABLETS 30's	R 458.21	1 x 30	14	5	90.00	180772047	CO
99	Desmopressin 0,2mg tablet, 30 tablets		8 180		Ferring (Pty) Ltd	MAAA0005879	VXY92	DDAVP 0.2mg TABLETS 30's	R 601.45	1 x 30	14	5	90.00	181795796	CO
101	Diazepam 5mg tablet, 100 tablets		59 800		Innovata Pharmaceuticals (Pty) Ltd	MAAA0003385	VBBL4	Doval 5 mg tablet	R 9.61	1 x 100	14	300	100.00	180280749	CO
102	Diazepam 5mg tablet, 14 tablets		61 100		Innovata Pharmaceuticals (Pty) Ltd	MAAA0003385	VBBL4	Doval 5 mg tablet	R 4.46	1 x 14	14	500	100.00	222001090	CO
103	Diazoxide 25mg capsule, 100 capsules		524		MSD (Pty) Ltd	MAAA0077142	V2185	Proglidem 25mg Capsules	R 455.65	1 x 100	14	1	90.00	189714440	CO
104	Digoxin 0,0625mg tablet, 100 tablets		8 970		Pharmacare Limited	MAAA0008452	V2205	LANOXIN P.G.0.0625MG TABS 120'S	R 102.47	1 x 120	14	100	95.00	181898753	CO
107	Digoxin 0.25mg tablet, 28 tablets		592 970		Pharmacare Limited	MAAA0008452	V2205	LANOXIN 0.25mg tablet, 30 tablets	R 13.06	1 x 30	14	100	95.00	222001091	CO
108	Dinoprostone 0.5mg scored tablet, 10 tablets Product Awarded: Dinoprostone 0.5mg unscored tablet, 10 tablets		18 070		Pfizer Laboratories (Pty) Ltd	MAAA0019202	V2189	Prostin E2 0.5mg	R 296.85	1 x 10	14	1	91.00	189710531	CO
109	Doxazosin 4mg tablet, 30 tablets	3 483 660	3 135 294	90%	Aurobindo Pharma (Pty) Ltd	MAAA0039785	V1MV2	Urodoxa 4 mg	R 18.89	1 x 30	14	1 x 30	94.00	189763013	CO
			348 366	10%	Mylan (Pty) Ltd	MAAA0081441	V3PS6	CARDUGEN 4 MG	R 27.74	1 x 30	14	100	50.83		

Item No	Item Specification	Estimate	Quantity Awarded	Split %	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price	Pack Size Offered: Unit Pack	Lead-Time (≤ 14 calendar days)	MOQ	Total Score	National Stock Number	UOM
111	Enalapril 10mg tablet, 28 tablets [Items 111 + 112 will be considered a series]	44 240 580	11 716 018	26.48%	Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	ENALAPRIL 10 BIOTECH	R 4.62	1 x 30	14	1	95.00	189708531	CO
			11 067 352	25.02%	Ranbaxy Pharmaceuticals (Pty) Ltd	MAAA0000384	V4728	ALAPREN 10 TABLETS	R 4.89	1 x 28	14	120	89.74		
			10 891 172	24.62%	Dezzo Trading 392 (Pty) Ltd	MAAA0006141	V05Y6	Enalapril Ascendis 10mg	R 5.22	1 x 28	14	100	88.31		
			10 566 038	23.88%	Pharma-Q (Pty) Ltd	MAAA0016762	V1NK1	Envas 10	R 5.15	1 x 28	14	350	85.68		
112	Enalapril 20mg tablet, 28 tablets [Items 111 + 112 will be considered a series]	8 690 620	6 083 434	70%	Ranbaxy Pharmaceuticals (Pty) Ltd	MAAA0000384	V4728	ALAPREN 20 TABLETS	R 6.90	1 x 28	14	120	95.00	181859964	PG
			2 607 186	30%	Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	ENALAPRIL 20 BIOTECH	R 6.93	1 x 30	14	1	86.00		
113	Enalapril 5mg tablet, 28 tablets	5 712 810	1 989 506	34.83%	Dezzo Trading 392 (Pty) Ltd	MAAA0006141	V05Y6	Enalapril Ascendis 5mg	R 3.94	1 x 28	14	50	100.00	189710188	CO
			1 901 442	33.28%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austell Enalapril 5 mg	R 4.09	1 x 28	14	10	95.57		
			1 821 862	31.89%	Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	ENALAPRIL 5 BIOTECH	R 4.09	1 x 30	14	1	91.57		
114	Ergocalciferol 50 000 IU tablet, 100 tablets		29 354		Pharmacare Limited	MAAA0008452	V2205	Lennon Calciferol 50 000 IU Tabs 100	R 239.26	1 x 100	14	10	95.00	189759820	CO
116	Ezetimibe 10mg tablet, 30 tablets		21 310		MSD (Pty) Ltd	MAAA0077142	V2185	Ezetrol 10 mg	R 270.48	1 x 30	14	1	90.00	181797762	CO
119	Ferrous salt, providing 50 to 65 mg elemental iron, alone or in combination with other elements/vitamins tablet/capsule, 100 tablets/capsules		508 040		Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	VITAFORCE FEROVITE 200mg 100's	R 17.25	1 x 100 tablets	14	1	91.25	181892378	CO
120	Ferrous salt, providing 50 to 65 mg elemental iron, alone or in combination with other elements/vitamins tablet/capsule, 28 tablets/capsules	9 761 390	5 856 834	60%	Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	VITAFORCE FEROVITE 200mg 28's	R 4.97	1 x 28 tablets	14	1	92.58	181923348	CO
			3 904 556	40%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	GULF FERROUS SULPHATE COMPOUND TABLETS	R 4.84	1 x 28 tablets	14	300	91.00		
121	Ferrous salt, providing 50 to 65 mg elemental iron, alone or in combination with other elements/vitamins tablet/capsule, 56 tablets/capsules		1 157 300		Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	VITAFORCE FEROVITE 200mg 56's	R 9.18	1 x 56 tablets	14	1	91.75	181923349	CO
122	Ferrous salt, providing 50 to 65 mg elemental iron, alone or in combination with other elements/vitamins tablet/capsule, 84 tablets/capsules		1 923 660		Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	VITAFORCE FEROVITE 200mg 84's	R 13.10	1 x 84 tablets	14	1	93.60	181923350	CO
125	Fluoxetine 20mg tablet/capsule, 28 tablets/capsules	783 140	469 884	60%	Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	FLUOXETINE BIOTECH 20 30's	R 6.72	1 x 30 capsules	14	1	91.09	189712353	CO
			313 256	40%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Fluoxetine 20 Oethmaan	R 6.44	1 x 28 capsules	14	10	90.00		

Item No	Item Specification	Estimate	Quantity Awarded	Split %	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price	Pack Size Offered: Unit Pack	Lead-Time (≤ 14 calendar days)	MOQ	Total Score	National Stock Number	UOM
126	Fluoxetine 20mg tablets/capsules, 100 tablets/capsules		155 510		Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Fluoxetine 20 Oethmaan	R 20.01	1 x 100 capsules	14	100	90.00	180106075	CO
127	Folic acid 5mg tablet, 100 tablets		851 110		Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	GULF FOLIC ACID 5	R 14.95	1 x 100	14	126	91.00	189757933	CO
128	Folic acid 5mg tablet, 28 tablets	17 738 880	10 643 328	60%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	GULF FOLIC ACID 5	R 5.73	1 x 28	14	300	91.00	189713751	CO
			7 095 552	40%	Ranbaxy Pharmaceuticals (Pty) Ltd	MAAA0000384	V4728	BE-TABS FOLIC ACID	R 5.99	1 x 28	14	250	90.92		
129	Furosemide 40mg tablet, 112 tablets		219 430		Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austell Furosemide 40 mg 112's	R 16.33	1 x 112	14	10	99.00	181859966	PG
130	Furosemide 40mg tablet, 250 tablets		32 470		Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Furosemide 40 Unimed	R 32.74	1 x 250	14	50	98.18	189711054	CO
131	Furosemide 40mg tablet, 28 tablets	6 546 750	5 237 400	80%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austell Furosemide 40 mg 28's	R 4.66	1 x 28	14	10	99.00	180339712	PG
			1 309 350	20%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Furosemide 40 Unimed	R 5.54	1 x 28	14	300	83.00		
132	Furosemide 40mg tablet, 56 tablets	2 136 030	1 708 824	80%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austell Furosemide 40 mg 56's	R 8.27	1 x 56	14	10	99.00	181798154	PG
			427 206	20%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Furosemide 40 Unimed	R 9.71	1 x 56	14	200	84.33		
133	Furosemide 40mg tablet, 84 tablets	497 430	397 944	80%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austell Furosemide 40 mg 84's	R 12.56	1 x 84	14	10	99.00	181798156	PG
			99 486	20%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Furosemide 40 Unimed	R 14.64	1 x 84	14	100	85.10		
134	Furosemide 500mg tablet, 100 tablets		11 770		Sanofi-Aventis SA (Pty) Ltd	MAAA0009069	V2160	LASIX 500MG 100 TABS	R 1 299.50	1 x 100	14	72	91.00	189710019	CO
135	Glibenclamide 5mg tablet, 100 tablets		12 655		Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	BIO GLIBENCLAMIDE 5 Tablets 100's	R 12.00	1 x 100	14	1	95.00	189710395	CO
136	Glibenclamide 5mg tablet, 28 tablets	1 679 240	1 343 392	80%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Diacare	R 3.99	1 x 28	14	400	95.50	180189209	PG
			335 848	20%	Pharmacare Limited	MAAA0008452	V2205	GLYCOMIN TABS 5MG 28'S BB	R 4.31	1 x 28	14	20	82.92		
137	Glibenclamide 5mg tablet, 56 tablets	1 379 240	965 468	70%	Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	BIO GLIBENCLAMIDE 5 TABLETS 56s PRP	R 6.00	1 x 56	14	400	95.00	180340162	PG
			413 772	30%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Diacare	R 6.67	1 x 56	14	300	89.95		
138	Glibenclamide 5mg tablet, 84 tablets		381 170		Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	BIO GLIBENCLAMIDE 5 TABLETS 84s PRP C	R 8.50	1 x 84	14	400	90.67	180340166	PG
139	Glimepiride 1mg tablet, 28 tablets [Items 139 + 140 + 141 will be considered a series]	1 704 690	1 534 221	90%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Glimepiride 1 Oethmaan	R 2.93	1 x 28	14	100	90.00	222001094	CO
			170 469	10%	Accord Healthcare (Pty) Ltd	MAAA0005335	V2MB8	Accord Glimepiride 1mg	R 4.83	1 x 30	14	50	32.64		
140	Glimepiride 2mg tablet, 28 tablets [Items 139 + 140 + 141 will be considered a series]	3 074 040	2 459 232	80%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Glimepiride 2 Oethmaan	R 4.60	1 x 28	14	100	90.00	222001095	CO
			614 808	20%	Accord Healthcare (Pty) Ltd	MAAA0005335	V2MB8	Accord Glimepiride 2mg	R 5.52	1 x 30	14	50	73.00		
141	Glimepiride 4mg tablet, 28 tablets [Items 139 + 140 + 141 will be considered a series]	2 341 660	1 639 162	70%	Accord Healthcare (Pty) Ltd	MAAA0005335	V2MB8	Accord Glimepiride 4mg	R 6.90	1 x 30	14	50	91.00	222001096	CO
			702 498	30%	Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Glimepiride 4 Oethmaan	R 7.42	1 x 28	14	100	83.22		

Item No	Item Specification	Estimate	Quantity Awarded	Split %	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price	Pack Size Offered: Unit Pack	Lead-Time (≤ 14 calendar days)	MOQ	Total Score	National Stock Number	UOM
144	Haloperidol 1,5mg tablet, 100 tablets		171 755		Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Haloperidol 1.5 Oethmaan	R 16.79	1 x 100	14	200	90.00	189710367	CO
145	Haloperidol 5mg tablet, 100 tablets		419 730		Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Haloperidol 5 Oethmaan	R 23.23	1 x 100	14	200	90.00	189710327	CO
146	Haloperidol 5mg tablet, 28 tablets		970 630		Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Haloperidol 5 Oethmaan	R 6.67	1 x 28	14	100	90.00	181923352	CO
147	Haloperidol 5mg tablet, 56 tablets		190 190		Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Haloperidol 5 Oethmaan	R 14.66	1 x 56	14	50	90.00	181923353	CO
148	Hydralazine 25mg tablet, 56 tablets		1 135 160		Sandoz SA (Pty) Ltd	MAAA0011663	VVZ69	SANDOZ HYDRALAZINE 25 MG 56s	R 26.69	1 x 56	14	50	91.00	181798157	PG
149	Hydralazine 25mg tablet, 84 tablets		217 360		Sandoz SA (Pty) Ltd	MAAA0011663	VVZ69	SANDOZ HYDRALAZINE 25mg 84s TABS	R 39.30	1 x 84	14	50	91.00	180091224	PK
150	Hydrochlorothiazide 12,5mg tablet, 28 tablets		44 562 180		Pharmacare Limited	MAAA0008452	V2205	RIDAQ TABS 12.5MG 28'S	R 4.10	1 x 28	14	140	95.00	181821883	PG
151	Hydrochlorothiazide 25mg tablet, 28 tablets	22 262 050	7 754 029	34.83%	Dezzo Trading 392 (Pty) Ltd	MAAA0006141	V05Y6	Hydrochlorothiazide 25 Ascendis	R 4.61	1 x 28	14	100	99.41	180190405	PG
			7 410 011	33.29%	Pharmacare Limited	MAAA0008452	V2205	RIDAQ TABS 25MG 28'S BB	R 4.35	1 x 28	14	140	95.00		
			7 098 010	31.88%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	GULF HYDROCHLOROTHIAZIDE 25	R 4.58	1 x 28	14	300	91.00		
153	Hyoscine butylbromide 10mg tablet, 10 tablets		4 482 510		Adcock Ingram Healthcare (Pty) Ltd	MAAA0036413	V2272	Scopex Tablets 10's	R 29.28	1 x 10	14	50 units per shipper	100.00	189711820	CO
155	Ibuprofen 200mg tablet, 15 tablets	25 236 800	7 182 089	28.46%	Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	IBUPROFEN 200 BIOTECH TABLETS 15's	R 3.26	1 x 15	14	50	95.00	180339460	PG
			6 579 137	26.07%	Adcock Ingram Healthcare (Pty) Ltd	MAAA0036413	V2272	Betagesic Tablets 15's	R 3.73	1 x 15	14	240 units per shipper	87.02		
			6 036 480	23.92%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Unifen 200	R 3.99	1 x 15	14	200	79.85		
			5 439 093	21.55%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austifen 200 mg 15's	R 4.24	1 x 15	14	10	71.94		
156	Ibuprofen 200mg tablet, 42 tablets	3 015 250	2 412 200	80%	Dezzo Trading 392 (Pty) Ltd	MAAA0006141	V05Y6	Ibusor 200	R 8.00	1 x 42	14	100	100.00	181798173	PG
			603 050	20%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Unifen 200	R 9.64	1 x 42	14	200	81.55		
157	Ibuprofen 200mg tablet, 84 tablets	1 832 740	1 104 000	60.24%	Ranbaxy Pharmaceuticals (Pty) Ltd	MAAA0000384	V4728	BETAPROFEN 200	R 13.51	1 x 84	14	200	95.00	180339461	PG
			728 697.4	39.76%	Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	IBUPROFEN 200 BIOTECH TABLETS 84's	R 16.17	1 x 84	14	50	77.28		
158	Ibuprofen 400mg 100 tablets		127 050		Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Unifen 400	R 33.32	1 x 100	14	50	93.17	180155533	CO
159	Ibuprofen 400mg tablet, 15 tablets	3 399 560	2 719 648	80%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Unifen 400	R 5.83	1 x 15	14	300	100.00	181923355	CO
			679 912	20%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austifen 400 mg 15's	R 6.65	1 x 15	14	10	86.34		
160	Ibuprofen 400mg tablet, 84 tablets		874 300		Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Unifen 400	R 27.55	1 x 84	14	50	100.00	189711816	CO
161	Indomethacin 25mg capsule, 100 capsules		573 560		Resmed Healthcare cc	MAAA0010098	VCEJ2	Acuflex	R 17.67	1 x 100	14	160	100.00	189714494	CO
162	Isosorbide dinitrate 10mg tablet, 84 tablets		801 150		Sandoz SA (Pty) Ltd	MAAA0011663	VVZ69	SANDOZ ISOSORBIDE TABS 10 MG 84	R 20.89	1 x 84	14	50	91.00	180146434	CO
163	Isosorbide dinitrate 5mg sublingual tablet, 50 tablets		667 070		Sandoz SA (Pty) Ltd	MAAA0011663	VVZ69	SANDOZ ISOSORBIDE TABS 5 MG 50	R 18.89	1 x 50	14	50	91.00	189710453	CO
164	Isosorbide mononitrate 20mg, 56 tablets		73 800		Pharmaco Distribution (Pty) Ltd	MAAA0044115	VBVW1	ISMO	R 161.00	1 x 56	14	5	90.00	181773023	CO
165	Lamotrigine 100mg tablet, 56 tablets		326 530		Aurobindo Pharma (Pty) Ltd	MAAA0039785	V1MV2	Girotec 100 mg	R 46.55	1 x 60	14	1 x 60	94.00	180108130	CO
166	Lamotrigine 200mg tablet, 56 tablets		31 640		Aurobindo Pharma (Pty) Ltd	MAAA0039785	V1MV2	Girotec 200 mg	R 90.45	1 x 60	14	1 x 60	94.00	180192399	CO
167	Lamotrigine 25mg tablet, 56 tablets		250 820		Strides Pharma (Pty) Ltd /Kahma Biotech (Joint Venture)	MAAA0119416	VB035	Lamotrigine 25 Strides	R 23.09	1 x 60	14	50	96.00	180108134	CO
168	Lamotrigine 50mg tablet, 56 tablets		312 350		Aurobindo Pharma (Pty) Ltd	MAAA0039785	V1MV2	Girotec 50 mg	R 30.25	1 x 60	14	1 x 60	94.00	180108137	CO

Item No	Item Specification	Estimate	Quantity Awarded	Split %	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price	Pack Size Offered: Unit Pack	Lead-Time (≤ 14 calendar days)	MOQ	Total Score	National Stock Number	UOM
172	Lansoprazole 30mg capsule, 28 capsules	6 807 230	2 671 157	39.24%	Adcock Ingram Healthcare (Pty) Ltd	MAAA0036413	V2272	Adco-Roznal 30mg Capsules 28's	R 15.10	1 x 28	14	162 units per shipper	100.00	222001099	CO
			2 518 675	37.00%	Cipla Medpro SA (Pty) Ltd	MAAA0006605	VXZ32	Lansoloc 30 (30's)	R 15.12	1 x 30	14	180	98.88		
			1 617 398	23.76%	Ranbaxy Pharmaceuticals (Pty) Ltd	MAAA0000384	V4728	RAN-LANSOPRAZOLE 30	R 20.64	1 x 28	14	70	61.98		
173	Leflunomide 10mg tablet, 30 tablets		3 620		Sanofi-Aventis SA (Pty) Ltd	MAAA0009069	V2160	ARAVA 10MG TABS 30	R 143.75	1 x 30	14	100	91.00	181781164	CO
174	Leflunomide 20mg tablet, 30 tablets		39 000		Cipla Medpro SA (Pty) Ltd	MAAA0006605	VXZ32	Lunar 20	R 140.30	1 x 30	14	80	99.00	181753191	CO
175	Levetiracetam 250mg tablets, 30 tablets		87 760		Dr Reddy's Laboratories (Pty) Ltd	MAAA0007549	V1A08	Redilev 250	R 29.33	1 x 30	14	1	90.00	181934912	CO
176	Levetiracetam 500mg tablets, 30 tablets		20 544		Dr Reddy's Laboratories (Pty) Ltd	MAAA0007549	V1A08	Redilev 500	R 54.05	1 x 30	14	1	90.00	222001100	CO
177	Levetiracetam 750mg tablets, 30 tablets		25 830		Dr Reddy's Laboratories (Pty) Ltd	MAAA0007549	V1A08	Redilev 750	R 80.50	1 x 30	14	1	90.00	181934915	CO
180	Levothyroxine sodium 0,05mg tablet, 28 tablets		998 050		Pharmacare Limited	MAAA0008452	V2205	ELTROXIN 50UG TAB 30	R 9.13	1 x 30	14	50	95.00	222001102	CO
182	Levothyroxine sodium 0,1mg tablet, 28 tablets		962 700		Pharmacare Limited	MAAA0008452	V2205	ELTROXIN 100UG TAB 30	R 11.45	1 x 30	14	50	95.00	222001104	CO
187	Loperamide 2mg tablet, 6 tablets	4 453 780	4 008 402	90%	Adcock Ingram Healthcare (Pty) Ltd	MAAA0036413	V2272	Adco-Loperamide 2mg tablet 6's	R 1.30	1 x 6	14	176 units per sipper	100.00	189710479	CO
			445 378	10%	Pharmacare Limited	MAAA0008452	V2205	GASTRON 2MG TABS 6'S	R 3.83	1 x 6	14	30	-80.15		
188	Lorazepam 1mg tablet, 100 tablets		80 790		Pharmacare Limited	MAAA0008452	V2205	TRANQIPAM 1MG TABS 100'S	R 101.03	1 x 100	14	20	95.00	189710157	CO
189	Lorazepam 2,5mg tablet, 100 tablets		21 430		Pharmacare Limited	MAAA0008452	V2205	TRANQIPAM 2.5MG TABS 100'S	R 158.23	1 x 100	14	20	95.00	189714603	CO
190	Losartan 100mg tablet, 28 tablets		351 700		Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austell Losartan 100 mg 28's	R 17.14	1 x 28	14	10	99.00	181936085	CO
191	Losartan 50mg tablet, 28 tablets		1 094 110		Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	LOSARTAN BIOTECH 50MG 30TABS	R 8.62	1 x 30	14	1	95.00	180184519	CO
193	Mesalazine 400mg tablet, 90 tablets		17 410		Equity Pharmaceuticals (Pty) Ltd	MAAA0007480	V1QZ3	Asacol Tablets	R 320.00	1 x 90	14	20	91.00	189762990	CO
194	Metformin 500mg tablet, 112 tablets		407 500		Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austell Metformin 500 mg 112's	R 19.07	1 x 112	14	6	99.00	222001105	CO
195	Metformin 500mg tablet, 56 tablets	9 081 490	3 249 897	35.79%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austell Metformin 500 mg 56's	R 9.49	1 x 56	14	10	99.00	180670492	PG
			3 027 440	33.34%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Diamin-500	R 10.31	1 x 56	14	144	92.22		
			2 804 153	30.88%	Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	METFORMIN 500 BIOTECH TABLETS 56's	R 10.50	1 x 56	14	400	85.42		
196	Metformin 500mg tablet, 84 tablets	3 845 130	2 691 591	70%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austell Metformin 500 mg 84's	R 14.14	1 x 84	14	6	99.00	180339480	PG
			1 153 539	30%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Diamin-500	R 15.20	1 x 84	14	112	93.25		
197	Metformin 850mg tablet, 28 tablets	1 335 730	801 438	60%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austell Metformin 850 mg 28's	R 7.52	1 x 28	14	10	96.92	189711806	CO
			534 292	40%	Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	METFORMIN 850 BIOTECH TABLETS 28's	R 7.35	1 x 28	14	400	95.00		
198	Metformin 850mg tablet, 56 tablets	7 640 380	6 112 304	80%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austell Metformin 850 mg 56's	R 13.21	1 x 56	14	10	99.00	180670494	PG
			1 528 076	20%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Diamin-850	R 15.00	1 x 56	14	112	87.80		

Item No	Item Specification	Estimate	Quantity Awarded	Split %	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price	Pack Size Offered: Unit Pack	Lead-Time (≤ 14 calendar days)	MOQ	Total Score	National Stock Number	UOM
199	Metformin 850mg tablet, 84 tablets	2 132 190	1 705 752	80%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austell Metformin 850 mg 84's	R 19.35	1 x 84	14	6	99.00	189711808	CO
			426 438	20%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Diamin-850	R 22.11	1 x 84	14	72	87.16		
200	Methylodopa 250mg tablet, 56 tablets		804 090		Pharmacare Limited	MAAA0008452	V2205	HYPOTONE 250MG 56 BB	R 50.11	1 x 56	14	140	95.00	189711810	CO
201	Methylodopa 250mg tablet, 84 tablets		881 340		Pharmacare Limited	MAAA0008452	V2205	HYPOTONE 250MG 84	R 71.68	1 x 84	14	140	95.00	189710812	CO
203	Methylphenidate 10mg tablet, 30 tablets		1 993 910		Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	Methylphenidate 10mg BIOTECH 30 tablets	R 24.95	1 x 30	14	1	95.00	189710452	CO
207	Metoclopramide 10mg tablet, 10 tablets	2 930 600	2 051 420	70%	Adcock Ingram Healthcare (Pty) Ltd	MAAA0036413	V2272	Adco-Contromet Tablets 10's	R 1.63	1 x 10	14	450 units per shipper	100.00	181798176	PG
			879 180	30%	Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	BIO METOCLPRAMIDE 10MG 10s	R 1.72	1 x 10	14	1	90.03		
208	Metoclopramide 10mg tablet, 100 tablets		59 060		Adcock Ingram Healthcare (Pty) Ltd	MAAA0036413	V2272	Adco-Contromet Tablets 100's	R 9.96	1 x 100	14	100 units per shipper	100.00	189711057	CO
211	Minoxidil 10mg tablet, 100 tablets		3 394		Pfizer Laboratories (Pty) Ltd	MAAA0019202	V2189	Loniten 10 mg	R 668.00	1 X 100	14	1	91.00	189714351	CO
212	Minoxidil 5mg tablet, 100 tablets		8 340		Pfizer Laboratories (Pty) Ltd	MAAA0019202	V2189	Loniten 5 mg	R 381.77	1 X 100	14	1	91.00	189714350	CO
213	Montelukast 10mg tablet, 28 tablets		32 550		Dr Reddy's Laboratories (Pty) Ltd	MAAA0007549	V1A08	Topraz 10	R 28.58	1 x 30	14	1	90.00	222001109	CO
214	Montelukast 4mg tablet, 28 tablets		2 980		Dr Reddy's Laboratories (Pty) Ltd	MAAA0007549	V1A08	Topraz 4	R 39.49	1 x 30	14	1	90.00	222001110	CO
215	Montelukast 5mg tablet, 28 tablets		20 400		Dr Reddy's Laboratories (Pty) Ltd	MAAA0007549	V1A08	Topraz 5	R 41.66	1 x 30	14	1	90.00	222001111	CO
216	Morphine 10mg modified release tablet, 60 tablets		25 418		Mundipharma (Pty) Ltd	MAAA0228483	V32G6	MST Continus	R 317.75	1 x 60	7	12 x 60	91.00	222001112	CO
217	Morphine 30mg modified release tablet, 60 tablets		21 230		Mundipharma (Pty) Ltd	MAAA0228483	V32G6	MST Continus	R 579.88	1 x 60	7	12 x 60	91.00	222001113	CO
218	Morphine 60mg modified release tablet, 60 tablets		2 600		Mundipharma (Pty) Ltd	MAAA0228483	V32G6	MST Continus	R 847.33	1 x 60	7	12 x 60	91.00	222001114	CO
219	Nicotinamide 100mg tablet, 28 tablets		263 190		Evohealth (Pty) Ltd	MAAA0010062	VFMA4	Nicotinamide 100mg tablet VH	R 7.89	1 x 28	14	600	100.00	180339515	PG
220	Nicotinamide 100mg tablet, 84 tablets		26 610		Evohealth (Pty) Ltd	MAAA0010062	VFMA4	Nicotinamide 100mg tablet VH	R 18.48	1 x 84	14	770	100.00	181917398	CO
221	Nifedipine 10mg capsule, 100 capsules		25 610		Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	BIO-NIFEDIPINE 10 CAPS 100's	R 65.32	1 x 100	14	1	95.00	189710326	CO
223	Nifedipine 5mg capsule, 100 capsules		17 070		Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	BIO-NIFEDIPINE 5 CAPS 100's	R 43.25	1 x 100	14	1	95.00	189710364	CO
226	Olanzapine 10mg tablet, 28 tablets		346 580		Ranbaxy Pharmaceuticals (Pty) Ltd	MAAA0000384	V4728	OLEANZ 10	R 22.43	1 x 28	14	100	95.00	180142326	CO
227	Olanzapine 2.5mg tablet, 28 tablets		77 240		Ranbaxy Pharmaceuticals (Pty) Ltd	MAAA0000384	V4728	OLEANZ 2.5	R 13.80	1 x 28	14	156	95.00	180959585	CO
228	Olanzapine 5mg tablet, 28 tablets		264 710		Ranbaxy Pharmaceuticals (Pty) Ltd	MAAA0000384	V4728	OLEANZ 5	R 18.98	1 x 28	14	180	95.00	180142318	CO
231	Omeprazole 20mg tablet/capsule, 14 tablets/capsules	3 539 140	3 185 226	90%	Dezzo Trading 392 (Pty) Ltd	MAAA0006141	V05Y6	Nozer	R 6.52	1 x 14 capsules	14	96	100.00	189762924	CO
			353 914	10%	Adcock Ingram Healthcare (Pty) Ltd	MAAA0036413	V2272	Adco-Omeprazole 20mg Capsules 14's	R 8.03	1 x 14 capsules	14	162 units per shipper	79.16		
233	Orphenadrine 50mg tablet, 28 tablets		2 493 630		Pharmacare Limited	MAAA0008452	V2205	PHENERINE TABS 50MG 28'S BB	R 19.14	1 x 28	14	100	95.00	180339583	PG
234	Orphenadrine 50mg tablet, 56 tablets		1 117 500		Pharmacare Limited	MAAA0008452	V2205	PHENERINE TABS 50MG 56'S BB	R 37.38	1 x 56	14	100	95.00	180339585	PG
235	Orphenadrine 50mg tablet, 84 tablets		397 210		Pharmacare Limited	MAAA0008452	V2205	PHENERINE TABS 50MG 84'S BB	R 53.18	1 x 84	14	100	95.00	180339586	PG
236	Oxazepam 10mg tablet, 100 tablets		38 210		Pharmacare Limited	MAAA0008452	V2205	PURATA TABS 10MG 100'S	R 42.99	1 x 100	14	50	95.00	189712225	CO
237	Oxazepam 30mg tablet, 100 tablets		13 120		Pharmacare Limited	MAAA0008452	V2205	PURATA TABS 30MG 100'S	R 58.31	1 x 100	14	50	95.00	189714612	CO

Item No	Item Specification	Estimate	Quantity Awarded	Split %	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price	Pack Size Offered: Unit Pack	Lead-Time (≤ 14 calendar days)	MOQ	Total Score	National Stock Number	UOM
238	Oxybutynin 5mg tablet, 84 tablets		159 960		Ipharma (Pty) Ltd	MAAA0003048	V8QU8	Oxyrest	R 40.00	1 x 84	14	1	90.00	222001116	CO
239	Pancreatin 150mg equivalent to Amylase 8000 FIP units, Lipase 10000 FIP units and Protease 600 FIP units per capsule, 100 capsules		13 048		Abbott Laboratories South Africa (Pty) Ltd	MAAA0030395	V2150	Creon 10000	R 535.90	1 x 100	14	1	91.00	181747895	CO
240	Pancreatin 300mg equivalent to Amylase 18 000 FIP units, Lipase 25000 FIP units and Protease 1000 FIP units per capsule, 100 capsules		15 840		Abbott Laboratories South Africa (Pty) Ltd	MAAA0030395	V2150	Creon 25000	R 1 089.23	1 x 100	14	1	91.00	180231590	CO
241	Pantoprazole 20mg tablet/capsule, 28 tablets/capsules	697 500	480 000	68.82%	Ranbaxy Pharmaceuticals (Pty) Ltd	MAAA0000384	V4728	PANTOCID 20	R 12.82	1 x 30 tablets	14	192	95.00	181923404	CO
			217 550	31.19%	Dr Reddy's Laboratories (Pty) Ltd	MAAA0007549	V1A08	Pentoz 20	R 16.25	1 x 30 tablets	14	1	65.92		
243	Paracetamol 500mg tablet, 100 tablets	5 610 870	2 180 683	38.87%	Adcock Ingram Healthcare (Pty) Ltd	MAAA0036413	V2272	Adco-Napamol tablets 100's	R 11.55	1 x 100	14	100 units per shipper	100.00	189753434	CO
			1 937 693	34.53%	Zimbili Pharma cc	MAAA0659559	VG1E9	Dynadol tablets	R 12.98	1 x 100	14	74	88.86		
			1 492 494	26.60%	Innovata Pharmaceuticals (Pty) Ltd	MAAA0003385	VBBL4	Painogestic Tablets	R 15.60	1 x 100	14	74	68.44		
244	Paracetamol 500mg tablet, 20 tablets	63 417 380	19 525 329	30.79%	Adcock Ingram Healthcare (Pty) Ltd	MAAA0036413	V2272	Adco-Napamol tablets 20's	R 2.64	1 x 20	14	240 units per shipper	100.00	180155484	PG
			12 669 276	19.98%	Zimbili Pharma cc	MAAA0659559	VG1E9	Dynadol Tablets	R 3.67	1 x 20	14	1000	64.89		
			10 672 367	16.83%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Zypol	R 3.97	1 x 20	14	400	54.66		
			10 410 550	16.42%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austell Paracetamol 500 mg	R 3.98	1 x 20	14	10	53.32		
			10 139 858	15.99%	Innovata Pharmaceuticals (Pty) Ltd	MAAA0003385	VBBL4	Painogestic Tablets	R 4.05	1 x 20	14	300	51.93		
247	Phenobarbitone 30mg tablet, 28 tablets		287 400		Ranbaxy Pharmaceuticals (Pty) Ltd	MAAA0000384	V4728	SEDABARB	R 4.50	1 x 28	14	250	95.00	180190436	PG
248	Phenobarbitone 30mg tablet, 56 tablets		142 280		Ranbaxy Pharmaceuticals (Pty) Ltd	MAAA0000384	V4728	SEDABARB	R 8.60	1 x 56	14	250	95.00	180339595	PG
249	Phenobarbitone 30mg tablet, 84 tablets		207 490		Ranbaxy Pharmaceuticals (Pty) Ltd	MAAA0000384	V4728	SEDABARB	R 13.40	1 x 84	14	250	95.00	180155499	PG
250	Phenytoin 100mg capsule/tablet, 100 capsules/tablets		64 460		Pharmacare Limited	MAAA0008452	V2205	PHENYTOIN CAPSULES 100MG 100'S	R 65.94	1 x 100 capsules	14	100	95.00	189715312	CO
251	Phenytoin 100mg capsule/tablet, 84 capsules/tablets		1 520 320		Pharmacare Limited	MAAA0008452	V2205	PHENYTOIN CAPS 100MG 84 BB	R 51.63	1 x 84 capsules	14	100	95.00	189711804	CO
252	Potassium chloride 600mg tablet, 100 tablets		561 810		Cipla Medpro SA (Pty) Ltd	MAAA0006605	VXZ32	Ultipot	R 78.20	1 x 100	14	25	99.00	181917399	CO
253	Pramipexole 0,125mg tablet, 100 tablets [Items 253 + 254 + 255 will be considered a series]		760		Pharmacare Limited	MAAA0008452	V2205	Pexasp 0.125MG Tabs 100's	R 128.57	1 x 100	14	10	95.00	222000147	CO
254	Pramipexole 0,25mg tablet, 100 tablets [Items 253 + 254 + 255 will be considered a series]		9 230		Pharmacare Limited	MAAA0008452	V2205	Pexasp 0.25MG Tabs 100's	R 151.84	1 x 100	14	10	95.00	181758021	CO
255	Pramipexole 1mg tablet, 100 tablets [Items 253 + 254 + 255 will be considered a series]		1 380		Pharmacare Limited	MAAA0008452	V2205	Pexasp 1MG Tabs 100's	R 279.24	1 x 100	14	10	95.00	181775649	CO
258	Prednisone 5mg tablet, 100 tablets		514 230		Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	TROLIC	R 18.75	1 x 100	14	300	91.00	189714134	CO

Item No	Item Specification	Estimate	Quantity Awarded	Split %	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price	Pack Size Offered: Unit Pack	Lead-Time (≤ 14 calendar days)	MOQ	Total Score	National Stock Number	UOM
259	Prednisone 5mg tablet, 28 tablets	4 772 880	3 818 304	80%	Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	TROLIC	R 5.07	1 x 28	14	300	91.00	181798179	CO
			954 576	20%	Ranbaxy Pharmaceuticals (Pty) Ltd	MAAA0000384	V4728	BE-TABS PREDNISONE 5MG	R 6.38	1 x 28	14	250	71.75		
260	Prednisone 5mg tablet, 40 tablets		14 000		Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	TROLIC	R 7.44	1 x 40	14	300	91.00	181892395	CO
261	Prednisone 5mg tablet, 56 tablets		635 240		Gulf Drug Company (Pty) Ltd	MAAA0009791	VTS03	TROLIC	R 10.19	1 x 56	14	300	91.00	181860002	PG
265	Promethazine 25mg tablet, 100 tablets		141 200		Sanofi-Aventis SA (Pty) Ltd	MAAA0009069	V2160	PHENERGAN 25MG TABS 100	R 33.29	1 x 100	14	140	91.00	189710049	CO
266	Propranolol 10mg tablet, 250 tablets		1 180		Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Prodorol 10 mg	R 27.24	1 x 250	14	100	100.00	189711059	CO
267	Propranolol 10mg tablet, 28 tablets		111 140		Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Prodorol 10 mg	R 4.58	1 x 28	14	500	96.32	181798180	CO
268	Propranolol 10mg tablet, 50 tablets		202 480		Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Prodorol 10 mg	R 6.65	1 x 50	14	300	100.00	189716004	CO
269	Propranolol 10mg tablet, 84 tablets		40 600		Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Prodorol 10 mg	R 10.91	1 x 84	14	200	100.00	181798181	CO
270	Propranolol 40mg tablet, 250 tablets		1 300		Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Prodorol 40 mg	R 50.26	1 x 250	14	250	100.00	189711060	CO
271	Propranolol 40mg tablet, 56 tablets		57 470		Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Prodorol 40 mg	R 13.78	1 x 56	14	200	100.00	189711802	CO
272	Propranolol 40mg tablet, 84 tablets		8 350		Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Prodorol 40 mg	R 18.27	1 x 84	14	100	100.00	180190493	CO
273	Pyridostigmine 10mg tablet, 50 tablets		27 350		Mylan (Pty) Ltd	MAAA0081441	V3PS6	MESTINON 10 MG	R 281.75	1 x 50	14	20	93.00	180000607	CO
274	Pyridostigmine 60mg tablet, 150 tablets		19 100		Mylan (Pty) Ltd	MAAA0081441	V3PS6	MESTINON 60 MG	R 1 265.00	1 x 150	14	20	93.00	189710277	CO
275	Pyridoxine (Vitamin B6) 25mg tablet, 100 tablets		351 280		Evohealth (Pty) Ltd	MAAA0010062	VFMA4	Pyridoxine 25mg tablet VH	R 7.98	1 x 100	14	770	100.00	189710278	CO
276	Pyridoxine (Vitamin B6) 25mg tablet, 28 tablets	17 891 610	14 313 288	80%	Evohealth (Pty) Ltd	MAAA0010062	VFMA4	Pyridoxine 25mg tablet VH	R 2.78	1 x 28	14	1000	100.00	180339610	PG
			3 578 322	20%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Pyridoxine 25mg	R 3.16	1 x 28	14	500	87.70		
278	Quetiapine 100mg tablet, 90 tablets		30 450		Dr Reddy's Laboratories (Pty) Ltd	MAAA0007549	V1A08	Dopaquel 100	R 64.75	1 x 90	14	1	90.00	180351237	CO
280	Quetiapine 200mg tablet, 60 tablets		23 190		Dr Reddy's Laboratories (Pty) Ltd	MAAA0007549	V1A08	Dopaquel 200	R 81.00	1 x 60	14	1	90.00	180351239	CO
281	Quetiapine 25mg tablet, 100 tablets		27 430		Dr Reddy's Laboratories (Pty) Ltd	MAAA0007549	V1A08	Dopaquel 25	R 29.84	1 x 100	14	1	90.00	180350983	CO
283	Quetiapine 300mg tablet, 60 tablets		8 910		Dr Reddy's Laboratories (Pty) Ltd	MAAA0007549	V1A08	Dopaquel 300	R 129.84	1 x 60	14	1	90.00	181867272	BT
293	Retinol (Vitamin A) 100 000 iu snip-off, soft gel capsule, 50 blue capsules		187 840		Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	VITAFORCE A100 000IU CAPS 50's	R 49.00	1 x 50	14	1	95.00	181798187	CO
294	Retinol (Vitamin A) 200 000 iu snip-off, soft gel capsule, 50 red capsules		315 850		Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	VITAFORCE A200 000IU CAPS 50's	R 72.00	1 x 50	14	1	95.00	181798190	CO
295	Retinol (Vitamin A) 50 000 iu snip-off, soft gel capsule, 50 white capsules		48 010		Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	VITAFORCE A50 000IU CAPS 50's	R 42.00	1 x 50	14	1	95.00	181798191	CO
297	Risedronic acid 35mg tablet, 4 tablets		59 780		Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	RISEDRONATE 35 BIOTECH TABLETS 4's	R 10.00	1 x 4	14	1	95.00	181786131	CO
299	Risperidone 0,5mg tablet, 28 tablets		279 760		Accord Healthcare (Pty) Ltd	MAAA0005335	V2MB8	Rispacor 0,5mg	R 4.60	1 x 30	14	50	91.00	181799554	CO
300	Risperidone 1mg tablet, 28 tablets		951 190		Accord Healthcare (Pty) Ltd	MAAA0005335	V2MB8	Rispacor 1mg	R 5.29	1 x 30	14	50	91.00	180339003	CO
301	Risperidone 2mg tablet, 28 tablets		1 352 410		Accord Healthcare (Pty) Ltd	MAAA0005335	V2MB8	Rispacor 2mg	R 5.52	1 x 30	14	50	91.00	180965107	CO
302	Risperidone 3mg tablet, 28 tablets		758 340		Accord Healthcare (Pty) Ltd	MAAA0005335	V2MB8	Rispacor 3mg	R 6.90	1 x 30	14	50	91.00	180964999	CO

Item No	Item Specification	Estimate	Quantity Awarded	Split %	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price	Pack Size Offered: Unit Pack	Lead-Time (≤ 14 calendar days)	MOQ	Total Score	National Stock Number	UOM
303	Rivaroxaban 10mg tablet, 30 tablets		4 070		Bayer (Pty) Ltd	MAAA0009623	V6390	Xarelto 10	R 488.51	1 x 30	14	1 x 30	90.00	181870433	CO
308	Rosuvastatin 10mg tablet, 28 tablets		771 650		Ranbaxy Pharmaceuticals (Pty) Ltd	MAAA0000384	V4728	ROSVATOR 10	R 8.97	1 x 30	14	180	95.00	181814486	CO
310	Senna extract equivalent to Sennosides A and B 13,5mg tablet, 20 tablets		1 897 710		Cipla Medpro SA (Pty) Ltd	MAAA0006605	VXZ32	Soflax Tablets	R 4.83	1 x 20	14	480	99.00	181826115	CO
312	Sildenafil 20mg tablet, 90 tablets		4 520		Pfizer Laboratories (Pty) Ltd	MAAA0019202	V2189	Revatio	R 2 465.11	1 x 90	14	50	91.00	181828390	CO
314	Simvastatin 10mg tablet, 28 tablets	15 603 130	5 328 202	34.15%	Strides Pharma (Pty) Ltd /Kahma Biotech (Joint Venture)	MAAA0119416	VB035	Simvastatin 10 Strides	R 6.12	1 x 30	14	200	93.43	189762856	CO
			5 142 256	32.96%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Unisim 10	R 6.60	1 x 28	14	250	90.17		
			5 132 672	32.90%	Ipharma (Pty) Ltd	MAAA0003048	V8QU8	Simcard 10	R 5.95	1 x 28	14	600	90.00		
315	Simvastatin 20mg tablet, 28 tablets	7 984 770	2 695 802	33.76%	Strides Pharma (Pty) Ltd /Kahma Biotech (Joint Venture)	MAAA0119416	VB035	Simvastatin 20 Strides	R 7.94	1 x 30	14	200	96.00	189762970	CO
			2 588 499	32.42%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Unisim 20	R 8.63	1 x 28	14	200	92.18		
			2 700 470	33.82%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austell Simvastatin 20 mg 28's	R 8.19	1 x 28	14	10	96.17		
317	Spiroglactone 100mg tablet, 60 tablets		5 360		Pharmacare Limited	MAAA0008452	V2205	SPIRACTIN TABS 100MG 60'S	R 139.00	1 x 60	14	60	95.00	189711050	CO
318	Spiroglactone 25mg tablet, 200 tablets		41 690		Sandoz SA (Pty) Ltd	MAAA0011663	VVZ69	SANDOZ SPIRONOLACTONE TABS 25 MG 200	R 98.00	1 x 200	14	50	91.00	189710245	CO
319	Spiroglactone 25mg tablet, 28 tablets	2 980 990	2 384 792	80%	Pharmacare Limited	MAAA0008452	V2205	SPIRACTIN 25MG TABS 28'S BB	R 13.00	1 x 28	14	100	95.00	181798184	PG
			596 198	20%	Sandoz SA (Pty) Ltd	MAAA0011663	VVZ69	SANDOZ SPIRONOLACTONE TABS 25 MG 30	R 14.90	1 x 30	14	50	77.85		
320	Spiroglactone 25mg tablet, 56 tablets		893 790		Sandoz SA (Pty) Ltd	MAAA0011663	VVZ69	SPIRONALACTONE TABS 25MG 56s	R 23.90	1 x 56	14	50	91.00	181747912	CO
321	Spiroglactone 25mg tablet, 84 tablets		25 910		Pharmacare Limited	MAAA0008452	V2205	SPIRACTIN 25MG TABS 84'S BB	R 44.54	1 x 84	14	100	95.00	181747914	CO
322	Sulfasalazine 500mg tablet, 100 tablets		239 650		Pfizer Laboratories (Pty) Ltd	MAAA0019202	V2189	Salazopyrin EN 500mg TAB	R 287.17	1 X 100	14	100	91.00	189714546	CO
325	Theophylline 200mg modified release tablet, 56 tablets		1 735 890		Sandoz SA (Pty) Ltd	MAAA0011663	VVZ69	SANDOZ THEOPHYLLINE TABS 200 MG 60	R 28.44	1 x 60	14	50	91.00	189762882	CO
326	Theophylline 300mg modified release tablet, 56 tablets		169 600		Sandoz SA (Pty) Ltd	MAAA0011663	VVZ69	SANDOZ THEOPHYLLINE TABS 300 MG 60	R 59.99	1 x 60	14	50	91.00	189762886	CO
327	Thiamine (Vitamin B1) 100mg tablet, 28 tablets	2 472 580	2 225 322	90%	Adcock Ingram Healthcare (Pty) Ltd	MAAA0036413	V2272	Vitamin B1 Tablets 28's	R 6.46	1 x 28	14	192 units per shipper	100.00	181798189	PG
			247 258	10%	Evohealth (Pty) Ltd	MAAA0010062	VFMA4	Thiamine 100mg tablet VH	R 8.88	1 x 28	14	1000	66.28		
328	Thiamine (Vitamin B1) 100mg tablet, 84 tablets		55 230		Evohealth (Pty) Ltd	MAAA0010062	VFMA4	Thiamine 100mg tablet VH	R 21.90	1 x 84	14	770	100.00	181917416	CO
329	Topiramate 100mg tablet, 56 tablets		31 000		Ranbaxy Pharmaceuticals (Pty) Ltd	MAAA0000384	V4728	TOPIEP 100	R 52.40	1 x 60	14	70	95.00	180208573	CO
330	Topiramate 15mg Sprinkle capsule, 60 capsules		60		Janssen Pharmaceutica (Pty) Ltd	MAAA0016328	VBKY6	Topamax 15mg	R 287.16	1 x 60	7	1	90.00	180962328	CO
331	Topiramate 25mg tablet, 56 tablets		39 320		Ranbaxy Pharmaceuticals (Pty) Ltd	MAAA0000384	V4728	TOPIEP 25	R 25.84	1 x 60	14	70	95.00	180208565	CO
332	Topiramate 50mg tablet, 56 tablets		38 630		Ranbaxy Pharmaceuticals (Pty) Ltd	MAAA0000384	V4728	TOPIEP 50	R 32.71	1 x 60	14	70	95.00	180208570	CO
333	Tramadol 100mg capsule/tablet, 60 capsules/tablets		175 204		Sandoz SA (Pty) Ltd	MAAA0011663	VVZ69	TRAMA-HEXAL SR 100MG 60 TABS	R 118.94	1 x 60 tablets	14	50	91.00	181761190	CO

Item No	Item Specification	Estimate	Quantity Awarded	Split %	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price	Pack Size Offered: Unit Pack	Lead-Time (≤ 14 calendar days)	MOQ	Total Score	National Stock Number	UOM
334	Tramadol 50mg capsule/tablet, 100 capsules/tablets	1 947 150	1 822 338	93.59%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austell Tramadol 50 mg	R 31.33	1 x 100 capsules	14	6	99.00	180155404	CO
			124 800	6.41%	Ranbaxy Pharmaceuticals (Pty) Ltd	MAAA0000384	V4728	DOLOTRAM CAPULES	R 33.64	1 x 100 capsules	14	24	88.36		
335	Tramadol 50mg capsule/tablet, 20 capsules/tablets	4 692 570	3 284 799	70%	Austell Pharmaceuticals (Pty) Ltd	MAAA0034946	V1A10	Austell Tramadol 50 mg	R 7.54	1 x 20 capsules	14	10	99.00	180070238	BX
			1 407 771	30%	Ranbaxy Pharmaceuticals (Pty) Ltd	MAAA0000384	V4728	DOLOTRAM CAPULES	R 7.82	1 x 20 capsules	14	60	91.66		
341	Tranexamic acid 500mg tablet, 30 tablets (Option 2)		351 281		Litha Pharma (Pty) Ltd (Acino Pharma)	MAAA0009244	VGS73	TRANIC	R 184.06	1 x 30	14	100	100.00	222000951	CO
342	Valproate sodium 100mg crushable tablet, 100 tablets		25 560		Sanofi-Aventis SA (Pty) Ltd	MAAA0009069	V2160	EPILIM CRUSHABLE 100MG TAB 100	R 122.10	1 x 100	14	56	91.00	181808859	CO
343	Valproate sodium 133,2mg and Valproic acid 58mg modified release tablet, 100 tablets		320 860		Sanofi-Aventis SA (Pty) Ltd	MAAA0009069	V2160	EPILIM CR 200MG TAB 100	R 60.09	1 x 100	14	50	91.00	180145714	CO
344	Valproate sodium 133,2mg and Valproic acid 58mg modified release tablet, 56 tablets		1 268 630		Sanofi-Aventis SA (Pty) Ltd	MAAA0009069	V2160	EPILIM CR 200MG TAB 56	R 36.58	1 x 56	14	72	91.00	181813970	CO
345	Valproate sodium 199,8mg and Valproic acid 87mg modified release tablet, 100 tablets		456 560		Sanofi-Aventis SA (Pty) Ltd	MAAA0009069	V2160	EPILIM CR 300MG TAB 100	R 77.62	1 x 100	14	24	91.00	180145716	CO
346	Valproate sodium 199,8mg and Valproic acid 87mg modified release tablet, 56 tablets		1 775 950		Sanofi-Aventis SA (Pty) Ltd	MAAA0009069	V2160	EPILIM CR 300MG TAB 56	R 46.40	1 x 56	14	42	91.00	181813972	CO
347	Valproate sodium 333mg and Valproic acid 145mg modified release tablet, 100 tablets		406 120		Sanofi-Aventis SA (Pty) Ltd	MAAA0009069	V2160	EPILIM CR 500MG TAB 100	R 116.74	1 x 100	14	24	91.00	180223205	CO
348	Valproate sodium 333mg and Valproic acid 145mg modified release tablet, 56 tablets		1 854 080		Sanofi-Aventis SA (Pty) Ltd	MAAA0009069	V2160	EPILIM CR 500MG TAB 56	R 69.50	1 x 56	14	42	91.00	181813974	CO
349	Venlafaxine 150mg tablet/capsule, 28 tablets/capsules		108 890		Adcock Ingram Healthcare (Pty) Ltd	MAAA0036413	V2272	Adco-Venlafaxine XR 150mg Capsules 30's	R 121.69	1 x 30 capsules	14	150 units per shipper	100.00	180358282	CO
350	Venlafaxine 37,5mg tablet/capsule, 28 tablets/capsules		6 000		Cipla Medpro SA (Pty) Ltd	MAAA0006605	VXZ32	Venlor XR 37,5	R 31.63	1 x 30 capsules	14	240	99.00	181851983	CO
351	Venlafaxine 75mg tablet/capsule, 28 tablets/capsules		101 440		Cipla Medpro SA (Pty) Ltd	MAAA0006605	VXZ32	Venlor XR 75	R 63.25	1 x 30 capsules	14	120	99.00	180358280	CO
352	Verapamil 240mg tablet, 28 tablets		37 910		Abbott Laboratories South Africa (Pty) Ltd	MAAA0030395	V2150	Isoptin SR 240 mg	R 58.65	1 x 30	14	10	91.00	189709075	CO
353	Verapamil 40mg tablet, 84 tablets		97 170		Oethmaan Biosims (Pty) Ltd	MAAA0437774	V91P2	Verapamil 40 Oethmaan	R 25.30	1 x 84	14	50	90.00	180339609	PG

LEGEND UNIT OF MEASURE (UOM)	
BT	Bottle
BX	Box
CO	Container
PG	Packaging Group (Patient Ready Pack)
PK	Prepack



SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT

HP09-2021SD

**THE SUPPLY AND DELIVERY OF SOLID DOSAGE FORMS TO THE DEPARTMENT OF
HEALTH FOR THE PERIOD 01 MAY 2021 TO 30 APRIL 2023**

BID VALIDITY PERIOD: 120 DAYS

CLOSING DATE AND TIME OF BID:

27 JULY 2020 AT 11H00

NO BRIEFING SESSION WILL BE HELD.



TABLE OF CONTENTS

ABBREVIATIONS.....	3	17. PARTICIPATING AUTHORITIES AND OTHER HEALTH ESTABLISHMENT	21
BID DOCUMENT CHECK LIST	5	18. REGISTRATION ON DATABASES OF PARTICIPATING AUTHORITIES	21
1. LEGISLATIVE AND REGULATORY FRAMEWORK.....	8	SECTION B	21
2. BID INFORMATION SESSION.....	8	19. POST AWARD PARTICIPATION.....	22
3. EVALUATION CRITERIA	8	20. AWARD CONDITIONS	22
SECTION A.....	8	21. NEGOTIATIONS	28
3.1 PHASE II: MANDATORY REQUIREMENTS.....	9	22. NON-COMMITMENT	28
3.1.1 LEGISLATIVE REQUIREMENTS TO THIS BID.....	9	23. PRICE REVIEW	28
3.1.2 RESPONSIVE BIDS	10	23.1 ELIGIBILITY RELATING TO RATE OF EXCHANGE ADJUSTMENTS.....	28
3.1.3 BID RESPONSE DOCUMENT	10	23.2 PRICE ADJUSTMENTS RELATING TO FOREIGN EXCHANGE RISK.....	29
3.1.4 AUTHORISATION DECLARATION.....	10	23.3 APPLICATION FOR CONTRACTUAL PRICE ADJUSTMENTS.....	30
3.1.5 TAX COMPLIANCE STATUS.....	11	23.4 ROUTINE PRICE ADJUSTMENTS.....	30
4. PHASE III: PRODUCT TECHNICAL COMPLIANCE.....	12	23.5 EXCEPTIONAL PRICE ADJUSTMENTS.....	31
4.2 COMPLIANCE WITH SPECIFICATIONS	13	23.6 PRICE ADJUSTMENTS BASED ON A SYSTEMATIC REVIEW	31
5. PHASE IV: PREFERENCE POINT SYSTEM.....	13	24. QUALITY	32
6. PREFERENCE FOR LOCALLY PRODUCED PRODUCTS.....	15	25. DELIVERY AND QUANTITIES	32
7. VALUE ADDED TAX.....	16	26. SUPPLIER PERFORMANCE MANAGEMENT.....	33
8. SUBMISSION OF BIDS	16	SECTION C	33
9. COMPLETION OF DOCUMENTS AND BID SUBMISSION	18	27. PACKAGING, LABELLING AND BARCODES.....	37
10. LATE BIDS.....	19	28. SHELF LIFE	39
11. COUNTER CONDITIONS.....	19	29. CEDING, MERGERS, TAKE OVERS AND CHANGES IN SUPPLIER DETAILS	39
12. FRONTING	19	30. THIRD PARTIES	40
13. SUPPLIER DUE DILIGENCE	20		
14. COMMUNICATION.....	20		
15. CONTACT DETAILS.....	20		
16. CONTRACT PERIOD	21		



ABBREVIATIONS

API	: Active Pharmaceutical Ingredient
BAC	: Bid Adjudication Committee
B-BBEE	: Broad-Based Black Economic Empowerment
CPA	: Contract Price Adjustment
CSD	: Central Supplier Database
EAN	: European Article Numbering
EME	: Exempted Micro Enterprise
GMP	: Good Manufacturing Practice
MCC	: Medicines Control Council
MHPL	: Master Health Products List
MPC	: Master Procurement Catalogue
NDoH	: National Department of Health
PPPFA	: Preferential Procurement Policy Framework Act
QSE	: Qualifying Small Enterprise
RoE	: Rate of Exchange
SAHPRA	: South African Health Products Regulatory Authority
SARS	: South African Revenue Service
SBD	: Standard Bidding Document
VAT	: Value- Added Tax

**BID DOCUMENT CHECK LIST**

All bid documents listed below must be sorted, filed and submitted in the **exact** compilation sequence as indicated below and the annexure attached.

Submission of bid documents is compulsory, unless it's not applicable and indicated as such in the "N/A" column.

All bid documents must be signed.

Bidders not complying to any of the requirements may be deemed to be non-responsive and will not be considered for evaluation

Compilation Sequence	Admin Code	Document Name	N/A	Yes	No	Remark
1	CL	Covering Letter				
2	BSRA	Bid Signature. Resolution/Authority to sign bid				
3	BFI	Bid/File Index				
4	PBD4.1	PBD 4.1: Contact Details of Bidder				
5	SBD5.1	SBD 1: Invitation to bid				
6	TCP	Tax Clearance Pin Issued				
7	CSD	CSD Registration report - A certified copy of latest and complete report. Note: CSD summary report will not be accepted.				
8	SBD4	SBD 4: Declaration of interest				
9	PBD9	PBD9: Directors: Categorisation by race, gender and disability				
10	SBD5	SBD5: The National Industrial Participation Programme				
11	SBD6	SBD 6(1): Preference Points Claimed (B-BBEE)				
12	BBBEE	Valid B-BBEE certificate (certified copy of the original) or Sworn Affidavit to claim preference points				



Compilation Sequence	Admin Code	Document Name	N/A	Yes	No	Remark
13	SBD8	SBD 8: Declaration of Past SCM Practices				
14	SBD9	SBD 9: Certificate of Independent Bid Determination				
15	PBD1	PBD1: Authorisation Declaration Note: Non-compliance to submission of a valid authorisation declaration, where applicable, may invalidate the bid.				
16	PBD1.1	PBD 1.1: List of products offered sourced from third party				
17	PBD1.2	PBD 1.2: Unconditional written undertaking from the third party.				
18	PBD5	PBD5: Good Manufacturing Practice (GMP). Declaration of compliance.				
19	PBD8	PBD 8: Special Requirements and Conditions of Contract. Declaration of compliance.				
20	CIPC	CIPC/CIPRO or proof of ownership/shareholding. Certified copies of registration certificates				
21	NC	Proof of company cedings, mergers and name changes				
22	LICMI	Licence to manufacture or import (in the name of the bidder), <u>including all annexures. Certified copies required.</u>				
23	LICM	Licence to manufacture medicines, including all annexures <u>for local manufacturing sites</u> as listed on the MRC of the bidder (applicant). Certified copies required.				
24	MRC	Medicine Registration Certificates (MRC) with all the associated conditions of registration - Certified copies <u>Note: All MRC's must be marked by the bidder with the relevant item number and be sorted and filed in numerical order.</u>				



Compilation Sequence	Admin Code	Document Name	N/A	Yes	No	Remark
25	PI	Original Package Insert (PI) or document detailing professional information approved by the Medicines Control Council (MCC) or the South African Health Products Regulatory Authority (SAHPRA) for each product offered. Note: All PI's must be marked with the relevant item number and be sorted and filed/submitted in numerical order.				
26	PS	Proof of sample submission				
27	BL	Bidder's item list (List of products offered)				
28	PRICE	Signed Excel Bid Response Pricing Schedule If the Excel Bid response Pricing Schedule is not signed in the space provided, the bid will not be considered for evaluation.				
All bid documents listed above must be sorted, filed and submitted in the exact order as indicated above						
Submission of supporting bid documents is compulsory, unless it's not applicable and indicated as such in the "N/A" column						

The bid document check list is available as **Annexure A** in an excel spreadsheet format and should be completed by all bidders and be submitted in hard copy and as part of the electronic copies of **"Set 3: Electronic version of bid documents"**



SECTION A

1. LEGISLATIVE AND REGULATORY FRAMEWORK

This bid and all contracts emanating there from will be subject to the Medicines and Related Substances Act, (Act 101 of 1965), Pharmacy Act, (Act 53 of 1974); Patents Act, 1978 (Act 57 of 1978); Trade Marks Act, 1993 (Act 194 of 1993); General Conditions of Contract issued in accordance with Treasury Regulation 16A published in terms of the Public Finance Management Act, 1999 (Act 1 of 1999). The Special Conditions of Contract (SCC) are supplementary to General Conditions of Contract (GCC). Where, however, the Special Conditions of Contract are in conflict with the General Conditions of Contract, the Special Conditions of Contract prevail.

2. BID INFORMATION SESSION

As the National Department of Health complies with the regulations made under the Disaster Management Act, 2002, published in the Gazette 18 March 2020 no briefing session or public bid opening will be held.

It is strongly **recommended** that all prospective bidders submit all enquiries to tenders@health.gov.za on time to allow the response to reach the bidders before the tender closes.

3. EVALUATION CRITERIA

The evaluation process will be conducted in phases as follows:

Phase I	Phase II	Phase III	Phase IV
Mandatory and other bid requirements	Product technical compliance	Price and B-BBEE	Recommendation and Award
Compliance with mandatory and other bid requirements	Compliance with technical specifications Test reports received from sample evaluation	Bids evaluated in terms of the 90/10 preference system	Recommendation and award



3.1 PHASE I: MANDATORY REQUIREMENTS

Bidders must submit all required documents indicated above with the bid documents at the closing date and time of the bid. During this evaluation phase, bidder's responses will be evaluated based on the documents submitted under mandatory requirements. This phase is not scored and bidders who fail to comply with all mandatory requirements will be disqualified.

3.1.1 LEGISLATIVE REQUIREMENTS TO THIS BID

Items offered must be registered in terms of section 15 of the Medicines and Related Substances Act, 1965 (Act 101 of 1965), and must comply with the conditions of registration for the duration of the contract.

A certified copy of the original Medicine Registration Certificate, issued in terms of section 15(3) (a) of the Medicines and Related Substances Act, 1965 (Act 101 of 1965), must be included with the bid for all items offered.

The bidder must be indicated as the applicant on the Medicines Registration Certificate.

The bidder offering a product must be the holder of a licence to manufacture or import medicines issued in terms of section 22C (1) (b) of the Medicines and Related Substances Act, 1965 (Act 101 of 1965) including all annexures. A **certified copy** of the original licence must be submitted by the bidder offering the product.

The bidder offering a product must submit a **certified copy** of the original **licence** to manufacture medicines, including all annexures for local manufacturing sites listed on the MRC of the bidder who must also be the applicant.

Where an item offered is not eligible for registration in terms of section 15(3) (a) of the Medicines and Related Substances Act, 1965 (Act 101 of 1965), a package insert of the item must be supplied.

Bidders must comply with the requirements of the Patents Act, 1978 (Act 57 of 1978) and the Trade Marks Act, 1993 (Act 194 of 1993). Where applicable, an explanation for any non-compliance must be



provided. In the case where a product is manufactured under a voluntary license issued by the patent holder of such a product, a letter authorising the marketing of the product, provided to the bidder by the patent holder must be submitted with the bid.

3.1.2 RESPONSIVE BIDS

Bidders are required to submit responsive bids by completing all the prices in the Excel Bid Response. **All prices must be submitted with 2 (two) decimals.** Document and response fields in the fillible PDF bid document. In this regard, bidder's attention is drawn to the document "Definition of fields in the Bid Response Document" explaining the different fields in the bid document.

3.1.3 BID DOCUMENTS

Bidders are required to submit responsive bids by completing all the prices, mandatory response fields and item questionnaires.

The excel bid response documents i.e. pricing schedule and Directors: Categorisation of race, gender and disability provided forms an integral part of the bid document and bidders must ensure that it is completed without changing the structure thereof. All pages must be signed.

The prices quoted must be furnished as all inclusive (incl. VAT) on the basis of supply and delivery.

All prices must be submitted with two (2) decimals.

The bid price offered for a product is deemed to be for the pack size as advertised in the item specification and the unit specified.

Prices submitted must not exceed the ex-manufacturer component of the Single Exit Price inclusive of VAT.

3.1.4 AUTHORISATION DECLARATION

Only the holder of a Medicines Registration Certificate issued in terms of the Medicines and Related Substances Act, 1965 (Act 101 of 1965), may submit a bid.



In the event that the Manufacturer, Packer or other entity, as listed on the certificate of registration are external third parties, the bidder must ensure that all legal, financial and supply arrangements have been mutually agreed upon between the bidder and these third parties.

Where a third party is involved in any capacity, the bidder must submit a duly completed and signed Authorisation Declaration (PBD1) for each such third party.

The National Department of Health reserves the right to verify any information supplied by the bidder in the Authorisation Declaration and, should the information be found to be false or incorrect, the National Department of Health will exercise any of the remedies available to it in the bid documents.

Failure to submit a duly completed and signed Authorisation Declaration, with the required annexure(s), in accordance with the above provisions, will invalidate the bid for such goods or services offered.

No agreement between the bidder and any third party will be binding on the National Department of Health.

3.1.5 TAX COMPLIANCE STATUS

The Central Supplier Database and the tax compliance status PIN are the approved methods of verifying the tax compliance status of a bidder. The South African Revenue Service does not issue Tax Clearance Certificates anymore but has introduced an online provision via eFiling, for bidders to print their own Tax Clearance Certificates which they can submit with their bids or price quotations.

It is a condition of this bid that the tax matters of the bidder be in order at any point in time, or that satisfactory arrangements have been made with SARS to meet the bidder's tax obligations.

It is a requirement that bidders grant a written confirmation when submitting this bid that SARS may, on an on-going basis during the tenure of the contract, disclose the bidder's tax compliance status and, by submitting this bid, such confirmation is deemed to have been granted.

Bidders are required to be registered on the **Government's Central Supplier Database** and to include in their bid **their Master Registration Number (Supplier Number)** in order to enable the institution to verify the supplier's tax status on the Central Supplier Database;



Foreign suppliers with neither South African tax obligations nor history of doing business in South Africa must complete the questionnaire on the SBD1. Where a recommendation for award of a bid has been made to a foreign bidder, the NDOH will submit the bidder's completed SBD1 to the South African Revenue Service to email address: GovernmentInstitute@sars.gov.za. The South African Revenue Service will issue a confirmation of tax obligations letter to the NDOH, confirming whether or not the foreign entity has tax obligations in South Africa

Should the recommended bidder fail to provide written proof of their tax compliance status, the NDOH will reject the bid submitted by the bidder.

The National Department of Health shall verify the bidder's tax compliance status through the CSD. Where consortia/joint ventures/sub-contractors are involved, each party must be registered on the Central Supplier Database and their tax compliance status will be verified through the Central Supplier Database. Bidders remain responsible to update their CSD information in line with the bid documents submitted for this bid.

4. PHASE II: PRODUCT TECHNICAL COMPLIANCE

4.1 SAMPLES TO BE SUBMITTED TO HEALTH ESTABLISHMENTS

All bidders are required to submit samples, including bidders who are currently supplying the National Department of Health with products to confirm the following:

- Compliance with specifications as set out in the bid document/item specification.
- Compliance of the product with the requirements of the Medicines and Related Substances Act, 1965 (Act 101 of 1965).

Failure to submit samples at both health establishments listed below will invalidate the bid for such items offered. Samples are required to be submitted to each (both) of the addresses indicated below prior to closing date and time of bid:



Mr Dumisani Malele Depot Manager Tel: 011 628 9131 Gauteng: Medical Supplies Depot Store 3 35 Plunkett Avenue Hurst Hill 2092	Mr Nisaar Mia Pharmaceutical Policy Specialist Tel: 021 483 5800 Western Cape: Department of Health 4th Floor, Cape Medical Depot 16 Chiappini Street Cape Town 8001
--	---

- No samples must be sent to the National Department of Health.
- Samples must be marked with the bid number, the item number as well as the bidder's name and address.
- Bidders must submit at least one original pack of each offer for evaluation.
- It is the responsibility of the bidder to ensure that samples have been received at the addresses provided above.
- All samples for awarded items will be retained for the period of the contract.
- All samples must be a true representation of the product which will be supplied.
- All samples submitted must include the package insert or document detailing professional information approved by the MCC or SAHPRA.
- Proof of sample submission, including a signed copy of the item list as received by the sample evaluation site, must be submitted with the bid documents at the closing date and time of the bid.

4.2 COMPLIANCE WITH SPECIFICATIONS

Items must comply with the specification as detailed in the bid document.

5. PHASE IV: PREFERENCE POINT SYSTEM

5.1 A MAXIMUM OF 80 OR 90 POINTS IS ALLOCATED FOR PRICE ON THE FOLLOWING BASIS:

$$P_s = 80 \left(1 - \frac{P_t - P_{\min}}{P_{\min}} \right) \quad \text{or} \quad P_s = 90 \left(1 - \frac{P_t - P_{\min}}{P_{\min}} \right)$$

Where
 P_s = Points scored for price of bid under consideration



Pt = Price of bid under consideration
Pmin = Price of lowest acceptable bid

5.2 POINTS AWARDED FOR B-BBEE STATUS LEVEL OF CONTRIBUTOR

In terms of Regulation 6(2) and 7(2) of the Preferential Procurement Regulations, preference points must be awarded to a bidder for attaining the B-BBEE status level of contribution in accordance with the table below:

B-BBEE Status Level of Contributor	Number of points (90/10 system)	Number of points (80/20 system)
1	10	20
2	9	18
3	6	14
4	5	12
5	4	8
6	3	6
7	2	4
8	1	2
Non-compliant contributor	0	0

For this tender, the 90/10 preference point system will be applied.

- Bidders are required to complete the preference claim form (SBD 6.1), and submit a valid certified copy of the original B-BBEE status level verification certificate, at the closing date and time of the bid in order to claim the B-BBEE status level point.
- The points scored by a bidder in respect of the level of B-BBEE contribution will be added to the points scored for price.
- Only bidders who have completed and signed the declaration part of the preference claim form and who have submitted a certified copy of an original B-BBEE status level certificate issued by a registered auditor, accounting officer (as contemplated in section 60(4) of the Close Corporation Act, 1984 (Act No. 69 of 1984)) or an accredited verification agency will be considered for preference points.
- Exempted Micro Enterprises (EME's) and Qualifying Small Enterprises (QSE's) must submit a Sworn Affidavit as prescribed by the B-BBEE Commission, Practice Guide 01 of 2019.
- Sworn Affidavits submitted by EME's and QSE will strictly be evaluated according to the guidelines as prescribed by the B-BBEE Commission.



- If the bidder fails to comply with the paragraphs above, the bidder will be deemed not to have claimed preference points for B-BBEE status level of contribution and will therefore be allocated a zero (0). The National Department of Health may, before a bid is adjudicated or at any time, require a bidder to substantiate claims it has made with regard to preference claimed. The points scored will be rounded off to the nearest two (2) decimals. In the event that two (2) or more bids have scored equal total points, the contract will be awarded to the bidder scoring the highest number of preference points for B-BBEE.
- A contract may, on reasonable and justifiable grounds, be awarded to a bid that did not score the highest number of points.

6. PREFERENCE FOR LOCALLY PRODUCED PRODUCTS

The National Department of Health reserves the right to consider locally produced products offered. Bidders are required to indicate on the Excel Bid Response Document where the products are manufactured.

In order to provide preference to locally produced products, the definition of a locally produced product will be limited to product formulation and conversion processes that use materials and components to manufacture medicines (including importation of raw material of active pharmaceutical ingredients (API) and of excipients for production of finished products) in the Republic of South Africa.

Where the National Department of Health gives preference to locally produced products, the quantities for these items will be allocated and awarded proportionately to locally produced products, provided this does not **negatively impact upon security of supply and affordability.**

Bids for products that qualify for this preference must comply with all of the following criteria:

- The South African Health Product Authority (SAHPRA) certificate of registration for a product lists the primary site of production as one that is located in the Republic of South Africa;
- The bidder offering a product must be the holder of a licence to manufacture or import medicines issued in terms of section 22C (1) (b) of the Medicines and Related Substances Act, 1965 (Act 101 of 1965) including all annexures. A **certified copy** of the original licence must be submitted by the bidder offering the product.
- The bidder offering a product must submit a **certified copy** of the original licence to manufacture medicines, including all annexures for local manufacturing sites listed on the MRC of the bidder who must also be the applicant.
- The reference price as published by National Department of Health has not been exceeded (if applicable);



- The site/s of manufacture and/or packaging for the product offered is located in South Africa;
- Demonstrated capacity to service the required volumes as evaluated in terms of the data provided in the Excel Bid Response Document;
- Previous supplier performance;
- Compliance to all other aspects contained in these Special Conditions of Contract

7. VALUE ADDED TAX

All bid prices must be inclusive of 15% Value-Added Tax. Failure to comply with this condition will invalidate the bid.

8. SUBMISSION OF BIDS

All bid documents listed below must be sorted, filed and submitted in the exact compilation sequence as indicated below and the annexure attached.

Submission of bid documents is mandatory, unless it's not applicable and indicated as such in the "N/A" column in the Bid Document Check List.

All bid documents must be signed.

Bidders not complying to any of the requirements may be deemed to be non-responsive and will not be considered for evaluation.

- Covering Letter i.e. limited stock availability of any item offered, non-compliance;
- Status relating to TAX, B-BBEE, License to Manufacture, Certificates etc. Bid Signature;
- Resolution/Authority to sign bid;
- Bid/File Index;
- PBD 4.1: Contact Details of Bidder;
- SBD 1: Invitation to bid;
- Tax Clearance Pin Issued;
- CSD Registration report - A certified copy of latest and complete report. Note: CSD summary report will not be accepted;
- SBD 4: Declaration of interest;
- PBD9: Directors: Categorisation by race, gender and disability;
- SBD5: The National Industrial Participation Programme;



- SBD 6(1): Preference Points Claimed (B-BBEE);
- Valid B-BBEE certificate (certified copy) or Sworn Affidavit to claim preference points;
- SBD 8: Declaration of Past SCM Practices;
- SBD 9: Certificate of Independent Bid Determination;
- PBD1: Authorisation Declaration Note: Non-compliance to submission of a valid authorisation declaration, where applicable, may invalidate the bid;
- PBD 1.1: List of products offered sourced from third party;
- PBD 1.2: Unconditional written undertaking from the third party;
- PBD5: Good Manufacturing Practice (GMP). Declaration of compliance;
- PBD 8: Special Requirements and Conditions of Contract. Declaration of compliance;
- CIPC/CIPRO or proof of ownership/shareholding. Certified copies of registration certificates;
- Proof of company cedings, mergers and name changes;
- Certified copy of Licence to manufacture or import (in the name of the bidder), including all annexures;
- Certified copy of Licence to manufacture medicines, including all annexures for local manufacturing sites as listed on the MRC of the bidder (applicant);
- Certified copies of Medicine Registration Certificates (MRC) with all the associated conditions of registration (Annexure). Note: All MRC's must be marked by the bidder with the relevant item number and be sorted and filed in numerical order;
- Original Package Insert (PI) or document detailing professional information approved by the Medicines Control Council (MCC) or the South African Health Products Regulatory Authority (SAHPRA) for each product offered. Note: All PI's must be marked with the relevant item number and be sorted and filed/submitted in numerical order;
- Proof of sample submission;
- Bidder's item list (List of products offered); and
- Signed Excel Bid Response Pricing Schedule (All prices must be submitted in 2 (two) decimals). If the Excel Bid response Pricing Schedule is not signed in the space provided, the bid will not be considered for evaluation



9. COMPLETION OF DOCUMENTS AND BID SUBMISSION

Bidders are required to submit three sets of bid documents according to the instructions below. All three sets must be submitted not later than the closing date and time. Set 2 and Set 3 must be included on a CD with Set 1 and submitted in a sealed package. The full name and address of the bidder, including the return address, the bid number and the closing date must be clearly indicated on the package. All fields must be completed. Where information requested is not relevant this should be indicated with N/A.

Set 1: Hard copy legally binding bid documents

Bidders must complete all SBD, PBD and Bid Response forms in black ink, typed. Where no electronic entry field is provided bidders must complete the forms in black ink, handwritten in capital letters. The signed hard copy of the bid document will serve as the legal bid document.

Bidders must submit their complete bid in hard copy format (paper document). The Chief Executive Officer, Chief Financial Officer, or authorised designee of the entity submitting the bid must sign the official signature pages. All pages in the complete bid document must be initialed by same with black ink. The use of correction fluid is not acceptable. Any change/s must be clearly indicated and initialed.

As the National Department of Health complies with the regulations made under the Disaster Management Act, 2002, published in the Gazette 18 March 2020 no briefing session or public bid opening will be held. However, Bidders must still ensure that bids are delivered on time to the correct address and deposited in the Tender Box. Late bids will not be accepted for consideration

Bidders must refrain from using binding methods like coil, comb, wire velobind, screw binding etc. It is requested that bidders pre-punch two holes on the left hand side of bid documents suitable for filing in a two hole lever arch file. Bid documents should be tied in parcels using string or rope that can be easily untied for filing purposes.

Set 2: PDF of Hard Copy, signed legal documents. (i.e. pdf of Set 1)

Bidders must submit a PDF version of the entire signed hardcopy bid, including all certificates and documents requested.



Set 3: Electronic version of bid documents

Bidders must submit the electronic versions (editable pdf) of all SBD and PBD documents, Bid Response Document and other relevant spreadsheets in Excel (not pdf).

All three sets of information must be submitted in order for the bid to be evaluated.

Bidders must ensure that the **price quoted** for a product (line item) on the Bid Response Document is for the unit pack as specified. No conversion factors will be applied.

10. LATE BIDS

Bids received after the closing date and time, at the address indicated in the bid documents, will not be accepted for consideration and, where practical, be returned unopened to the bidder.

11. COUNTER CONDITIONS

Bidders' attention is drawn to the fact that amendments to any of the bid conditions or setting of counter conditions by bidders may result in the invalidation of such bids.

12. FRONTING

The National Department of Health supports the spirit of broad based black economic empowerment and recognises that real empowerment can only be achieved through individuals and businesses conducting themselves in accordance with the Constitution and in an honest, fair, equitable, transparent and legally compliant manner. Against this background, the National Department of Health condemns any form of fronting.

The National Department of Health, in ensuring that bidders conduct themselves in an honest manner will, as part of the bid evaluation processes, conduct or initiate the necessary enquiries/investigations to determine the accuracy of the representation made in bid documents. Should any of the fronting indicators as contained in the Guidelines on Complex Structures and Transactions and Fronting, issued by the Department of Trade and Industry, be established during such enquiry/investigation, the onus will be on the bidder/contractor to prove that fronting does not exist. Failure to do so within a period of 14 days from date of notification, may invalidate the bid/ contract and may also result in the restriction of the bidder/contractor to conduct business with the public sector for a period not exceeding 10 years, in addition to any other remedies the National Treasury may have against the bidder/contractor concerned.



13. SUPPLIER DUE DILIGENCE

The National Department of Health reserves the right to conduct supplier due diligence prior to final award or at any time during the contract period. This may include site visits to assess whether an item is manufactured at the site specified in the bid and the site complies with quality criteria.

14. COMMUNICATION

The National Department of Health, may communicate with bidders where clarity is sought after the closing date and time of the bid and prior to the award of the contract, or to extend the validity period of the bid, if necessary. Any communication to any government official or a person acting in an advisory capacity for the National Department of Health in respect of this bid between the closing date and the award of the bid by the bidder is discouraged.

All communication between the bidder and the National Department of Health, must be done in writing.

15. CONTACT DETAILS

Postal address

Directorate: Affordable Medicines

Private Bag X828

PRETORIA

0001

Physical address

Directorate: Affordable Medicines

Civitas Building

242 Struben Street

Cnr Thabo Sehume Street

Pretoria

0002

Please use the following e-mail address for any queries relating to bidding process:

- tenders@health.gov.za



SECTION B

16. CONTRACT PERIOD

The contract shall be for the period from 01 May 2021 to 30 April 2023.

17. PARTICIPATING AUTHORITIES AND OTHER HEALTH ESTABLISHMENTS

Participating Authorities and Health Establishments which will be participating authorities in this contract are National Departments, Provincial Departments and other institutions as approved by the accounting officer.

Provincial Departments:

- Eastern Cape;
- Free State;
- Gauteng;
- KwaZulu-Natal;
- Limpopo.
- Mpumalanga;
- Northern Cape;
- North West;
- Western Cape; and

Other Institutions:

- Nelson Mandela Children's Hospital

18. REGISTRATION ON DATABASES OF PARTICIPATING AUTHORITIES

All contracted suppliers must register on the supplier databases of Participating Authorities within 30 days after award of contract.

Failure to meet this requirement will result in the inability to process payment for goods.



19. POST AWARD PARTICIPATION

Regulation 16A6.6 of the Treasury Regulations for Departments, Trading Entities, Constitutional Entities and Public Entities, issued in terms of the Public Finance Management Act, 1999, (Act 1 of 1999), states that the Accounting Officer/Accounting Authority may, on behalf of a department, constitutional institution or public entity, request to participate in any contract arranged by means of a competitive bidding process by any organ of state, subject to the written approval of such organ of state and the relevant contractors.

20. AWARD CONDITIONS

The National Department of Health reserves the right to award contracts to more than one contractor for the same item.

The National Department of Health reserves the right to negotiate prices.

The National Department of Health reserves the right to award the same item as a multiple award to various contractors (two or more) to address high volume requirements, security of supply and product availability.

The following are examples of considerations which may be taken into account when contemplating a multiple award:

- Source of Active Pharmaceutical Ingredient (API) and actual manufacturing site;
- Capacity to meet expected demand as per published estimates in the Excel Bid Response Document;
- Estimated volume to be supplied;
- Risk to public health if the item is not available;
- Past compliance of the bidder with contractual obligations.

In cases where the tender does not achieve the most economically advantageous price, the National Department of Health reserves the right not to award that item. In the case of medicines for chronic conditions, pack sizes suitable for a 28-day treatment cycle are required. Should a 30-day or other pack size be offered, no conversion factor will be applied. Direct comparisons will be made between the 28-day and other pack sizes during evaluation. Similarly, no conversion factors will be applied in cases where a pack size other than that specified is offered.



The National Department of Health may change treatment protocols and/or product formulations where required, due to emerging clinical evidence, disease profiles, safety or resistance patterns and availability of items registered in terms of the Medicines and Related Substances Act, 1965, (Act 101 of 1965) at the date and time of bid closure. In these circumstances, the National Department of Health reserves the right to cancel the contract for an item, or adjust the quantity awarded based on expected changes in projected demand. The Department of Health will notify the contracted supplier within a reasonable time of the expected change. However, in cases where patient safety is a concern, these changes may be implemented with immediate effect.

20.1 SPLIT AND MULTIPLE AWARDS

The National Department of Health reserves the right to issue split or multiple awards, where necessary, to ensure security of supply.

The following will be taken into consideration when contemplating a split award:

- Source of API and manufacturing site.
- Capacity to meet expected demand as per published estimates in the Bid Response Document.
- Estimated volume to be supplied.
- Risk to public health if the item is not available.
- Past compliance of the bidder with contractual obligations.

Two-way split awards will be made in accordance with the following schedule based on the points scored:

Category	Difference between points scored	Recommended percentage split
A	Equal points	50/50
B	< 5 points	60/40
C	>5-10 points	70/30
D	>10-20 points	80/20
E	>20 points	90/10



Where a split for more than 2 suppliers is contemplated, the following formula may be used to allocate volumes for award:

- For a three way split: Supplier share = 33.3% + (supplier score - mean score) x 2.3%
- For a four way split: Supplier share = 25% + (supplier score - mean score) x 2%

20.2 THERAPEUTIC CLASS AWARDS

The Policy for Classifying Medicines into Therapeutic Classes for Purposes of Therapeutic Interchange defines a therapeutic class as a group of medicines which have active ingredients with comparable therapeutic effects. Medicines in a therapeutic class may or may not belong to the same pharmacological class, may differ in chemistry or pharmacokinetic properties, and may possess different mechanisms of action, result in different adverse reactions, have different toxicity and drug interaction profiles. In most cases, these medicines have close similarity in efficacy and safety profiles, when administered in equipotent doses for a specific indication.

The ministerially appointed National Essential Medicines List Committee (NEMLC) formulates and revises the Standard Treatment Guidelines (STGs) and Essential Medicines List (EML). Therapeutic classes are mentioned in the “Medicine treatment” section of the national STGs which provides a class of medicines followed by an example such as, HMGCoA reductase inhibitors (Statins) e.g. simvastatin. These therapeutic classes have been designated where none of the members of the class offer any significant benefit over member of the class for a specific indication. The NEMLC will designate therapeutic classes for a condition, where appropriate.

Such therapeutic classes may be used during the contracting process to achieve the most economically advantageous contract, offer the market the largest volume and increase the number of competitors, thereby offering the opportunity for cost efficiencies by stimulating robust competition.

A single member of the class may be awarded.



Therapeutic Class and Series Number	Therapeutic class description	Members of the therapeutic class
Class 1	Proton Pump Inhibitors (Standard dose-28 day pack)	Lansoprazole 30mg capsule, 28 capsules Vs Omeprazole 20mg tablet/capsule, 28 tablets/capsules Vs Pantoprazole 40mg tablet/capsule, 28 tablets/capsules Vs Rabeprazole 20mg tablet/capsule, 28 tablets/capsules
Class 2	HMG CoA Reductase Inhibitors: Intermediate Dose	Atorvastatin 20mg tablet, 30 tablets Vs Pravastatin 40mg tablet, 30 tablets Vs Rosuvastatin 10mg tablet, 28 tablets Vs Simvastatin 40mg tablet, 30 tablets
Class 3	Nitrates, short acting	Glyceryl trinitrate 0,5mg sublingual tablet, 50 tablets Vs Isosorbide dinitrate 5mg sublingual tablet, 50 tablets
Class 4	Calcium Channel Blocker: Low dose	Amlodipine 5mg tablet, 28 tablets Vs Felodipine 5mg tablet, 30 tablets Vs Nifedipine 30mg modified release tablet, 28 tablets
Class 5	Calcium Channel Blocker: High dose	Amlodipine 10mg tablet, 28 tablets Vs Felodipine 10mg tablet, 30 tablets Vs Nifedipine 60mg modified release tablet, 28 tablets



Therapeutic Class and Series Number	Therapeutic class description	Members of the therapeutic class
Class 6 Series 1 to 6	Ace-Inhibitors [low dose]	Enalapril 10mg tablet, 28 tablets, (Series 1) Vs Lisinopril 10mg tablet, 28, (Series 2) Vs Perindopril 4mg tablet, 28, (Series 3) Vs Quinapril 10mg tablet, 28 tablets, (Series 4) Vs Ramipril 2,5mg tablet/ capsule, 28 tablets/capsules, (Series 5) Vs Trandolapril 0,5mg capsule, 30, (Series 6)
Class 7 Series 1 to 6	Ace-Inhibitors [high dose]	Enalapril 20mg tablet, 28 tablets, (Series 1) Vs Lisinopril 20mg tablet, 28 tablets, (Series 2) Vs Perindopril 8mg tablet, 28 tablets, (Series 3) Vs Quinapril 20mg tablet, 28 tablets, (Series 4) Vs Ramipril 5mg tablet/ capsule, 28 tablets/capsules, (Series 5) Vs Trandolapril 2mg capsule, 30 capsules, (Series 6)
Class 8	Bisphosphonates	Alendronic acid 10mg tablet, 28 tablets Vs Alendronic acid 70mg tablet, 4 tablets Vs Risedronic acid 35mg tablet, 4 tablets Vs Risedronic acid 5mg tablet, 28 tablets
Class 9	Alpha-receptor blocker	Alfuzosin 10mg tablet, 30 tablets Vs Doxazosin 4mg tablet, 30 tablets Vs Silodosin 8mg capsule, 30 capsules Vs Tamsulosin 0,4mg capsule, 28 capsules Vs Terazosin 10mg tablet, 28 tablets



Therapeutic Class and Series Number	Therapeutic class description	Members of the therapeutic class
Class 10	Proton Pump Inhibitors (Standard dose-14 day pack)	Lansoprazole 30mg capsule, 14 capsules Vs Omeprazole 20mg tablet/capsule, 14 tablets/capsules Vs Rabeprazole 20mg tablet/capsule, 14 tablets/capsules
Class 11	Proton Pump Inhibitors (Low dose)	Lansoprazole 15mg tablet/capsule, 28 tablets/capsules Vs Omeprazole 10mg tablet/capsule, 28 tablets/capsules Vs Pantoprazole 20mg tablet/capsule, 28 tablets/capsules Vs Rabeprazole 10mg tablet/capsule, 28 tablets/capsules
Class 12	SSRI - higher dose	Citalopram 20mg tablet, 28 tablets Vs Escitalopram 10mg tablets, 30 tablets Vs Sertraline 100mg tablets, 30 tablets
Class 13	Not named	Aspirin 100mg tablet, 28 tablets Vs Aspirin 300mg scored tablet, 14 tablets
Class 14	HMG CoA Reductase Inhibitors: Intermediate dose with myalgia	Atorvastatin 10mg tablet, 28 tablets Vs Pravastatin 40mg tablet, 30 tablets Vs Rosuvastatin 5mg tablet, 28 tablets Vs Simvastatin 20mg tablet, 28 tablets

20.3 OPTION AWARDS

Bids are invited based on the options contained in the scenarios below. The National Department of Health will award either (*Option 1*) or (*Option 2*).

Item No	Item Description	Estimate
339	Tranexamic acid 500mg tablet, 100 tablets (<i>Option 1</i>)	7 370
340	Tranexamic acid 500mg tablet, 30 tablets (<i>Option 1</i>)	109 000



Item No	Item Description	Estimate
341	Tranexamic acid 500mg tablet, 30 tablets (<i>Option 2</i>)	351 281

- Option 1 requires a combination of pack sizes (100 and 30 tablets respectively),
- Option 2 requires a pack size of 30 tablets.

21 NEGOTIATIONS

The National Department of Health reserves the right to negotiate with the bidders prior to award and with the successful bidder(s) post award.

22. NON-COMMITMENT

The National Department of Health reserves the right not to award, to award in part, or in full.

The right is also reserved to withdraw or amend any of the bid conditions, by notice, in writing to all bidders prior to closing of the bid and post award

In the event that an incorrect award has been made, the National Department of Health reserves the right to remedy the matter in any manner it may deem fit.

23. PRICE REVIEW

The National Department of Health envisages three types of price review processes for the duration of this contract:

- A routine adjustment to mitigate foreign exchange fluctuations;
- An exceptional adjustment to mitigate significant short-term foreign exchange fluctuations; and
- A systematic review of prices for comparable products available in the international market place.

23.1 ELIGIBILITY RELATING TO RATE OF EXCHANGE ADJUSTMENTS

Eligibility for price adjustments relating to foreign exchange risk depends on:

The submission of a complete price breakdown per instructions below for all relevant products; and

Assessment of the rationality of this price breakdown by the National Department of Health.



23.1.1 INSTRUCTIONS FOR PRICE BREAKDOWN

- The price breakdown must be completed on the signed bid response document as well as the electronic version. The delivered price must be divided across five components
 - Active Pharmaceutical Ingredients (API);
 - Formulation;
 - Packaging;
 - Logistics (this includes transportation, warehousing and distribution);
 - Gross margin (remaining portion).
- The sum of these categories must be equal to 100% of the delivered price for the line item.
- The local + imported portions of the first three components must add up to 100% within each component (e.g. Portion of API attributable to local + Portion of API attributable to import = 100% of specific API component).
- VAT must be apportioned equally across all components and not regarded as a separate component.
- Labour must be apportioned appropriately across the relevant components.
- Breakdown must be in percentage format to the closest whole percentage (e.g. 20%).
- The National Department of Health reserves the right to engage with bidders to verify any of the components of the bid price, which may include audit of invoices and related documentation.

23.2 PRICE ADJUSTMENTS RELATING TO FOREIGN EXCHANGE RISK

Only the portion of the bid price facing foreign exchange risk will be adjusted. This portion is determined by the price breakdown on the signed bid submission.

Adjustments are always calculated using the original awarded contracted price as the base.

Price adjustments relating to foreign exchange will be based on the percentage change between the relevant base average rate of exchange (RoE) and an adjustment average RoE.

Rates are sourced from the Reserve Bank (www.resbank.co.za).

Eligibility for favourable Contractual Price Adjustments may be withdrawn in light of evidence of poor compliance with contractual obligations.



Base average RoE for this tender will be as follows, per currency:

Currency	Base Average Rates of Exchange Average for the period 1 December 2019 to 31 May 2020
Rand per US Dollar	16.18
Rand per Br Pound	20.49
Rand per Euro	17.78
Rand per Yuan Renminbi	2.28
Rand per Indian Rupee	0.22

Should the bidder make use of any currency not mentioned above, the bidder must stipulate this clearly and submit the calculated average RoE for the period 1 December 2019 to 31 May 2020 using the South African Reserve Bank published rates for the specific currency.

23.3 APPLICATION FOR CONTRACTUAL PRICE ADJUSTMENTS

Scanned copies of signed applications for price adjustments must be received by the National Department of Health prior to the submission dates detailed in the tables below.

Where no application for an adjustment relating to foreign exchange has been received and such an adjustment would be favourable to the Department, this will be implemented automatically.

Foreign exchange adjustments may never result in a price exceeding the current Single Exit Price, ex Logistics.

23.4 ROUTINE PRICE ADJUSTMENTS

Schedules for routine price reviews, and periods for calculating adjustment average RoE are detailed in the table below:

Review	Period for calculating adjustment average RoE	Submission of request for price review to reach the office by	Date from which adjusted prices will become effective
1	01 May 2021 - 31 October 2021	03 November 2021	01 December 2021
2	01 November 2021 - 30 April 2022	03 May 2022	01 June 2022
3	01 May 2022 - 31 October 2022	03 November 2022	01 December 2022



23.5 EXCEPTIONAL PRICE ADJUSTMENTS

Suppliers may request exceptional price adjustments according to the schedule in the table below. These will be activated if the absolute change between the base RoE and the three month retrospective average RoE indicated in the table below fluctuates by more than 10%.

Review	Period for calculating adjustment average RoE	Submission of request for price review to reach the office by	Date from which adjusted prices will become effective
0.1	01 May 2021 - 31 July 2021	03 August 2021	01 September 2021
1.1	01 November 2021 - 31 January 2022	03 February 2022	01 March 2022
2.1	01 May 2022 - 31 July 2022	03 August 2022	01 September 2022
3.1	01 November 2022 - 31 January 2023	03 February 2023	01 March 2023

Suppliers who received exceptional adjustments will receive routine adjustments based on the preceding three months, rather than the usual six month historical average exchange rate. The periods for calculating adjustment average RoE in these instances are detailed in the table below:

Review	Period for calculating adjustment average RoE post exceptional adjustment	Submission of request for price review to reach the office by	Date from which adjusted prices will become effective
1	01 August 2021 - 31 October 2021	03 November 2021	01 December 2021
2	01 February 2022 - 30 April 2022	03 May 2022	01 June 2022
3	01 August 2022 - 31 October 2022	03 November 2022	01 December 2022

23.6 PRICE ADJUSTMENTS BASED ON A SYSTEMATIC REVIEW

The National Department of Health reserves the right to review international prices to identify lowest comparable global prices.

Where this review identifies any prices that are lower than contract prices the National Department of Health will enter into price negotiations with the contracted supplier.



Where the outcome of this negotiation is deemed unfavourable, the National Department of Health reserves the right to terminate the award for the item in question.

24. QUALITY

Products must conform to the conditions of registration of the product in terms of the Medicines and Related Substances Act, 1965 (Act 101 of 1965) for the full duration of this contract.

25. DELIVERY AND QUANTITIES

25.1 DELIVERY BASIS

Firm lead times for delivery must be quoted for the duration of the contract period.

Transit and storage conditions applicable to the relevant products must be adhered to.

The initial lead time as proposed in the bid response document will be calculated from date of award of the contract and NOT the date of placement of the first order. This period may not exceed 75 calendar days from the date of award.

Lead time within the contract period is defined as the time from submission of order to supplier to time of receipt by the Department, as confirmed by the Proof of Delivery document. This lead time may not exceed 14 calendar days.

Failure to comply with the contractual lead time will result in penalties being enforced as per paragraph 21 and 22 of the General Conditions of Contract.

25.2 QUANTITIES

The quantities reflected in the bid are estimated quantities and no guarantee is given or implied as to the actual quantity which will be procured during the contract period. Fluctuations in monthly demand may occur.

Proposed minimum order quantities (MOQs) should facilitate delivery directly to health establishments. The National Department of Health reserves the right to negotiate MOQs where necessary. Where consensus regarding MOQs cannot be reached, the bid may not be awarded.

Suppliers are required to maintain sufficient buffer stock to meet at least two-months demand for all items, aligned with the needs of Participating Authorities.



SECTION C

26. SUPPLIER PERFORMANCE MANAGEMENT

26.1 Supplier performance management will be the responsibility of Participating Authorities with oversight from the National Department of Health and, where supplier performance disputes cannot be resolved between the contractor and the Participating Authority, National Treasury: Transversal Contracting Chief Directorate and National Department of Health must be informed for corrective action.

The National Department of Health, in collaboration with the Participating Authorities, will monitor the performance of contracted suppliers in terms of this contract, including but not limited to the following:

- Compliance with reporting requirements according to reporting schedule and reporting mechanism.
- As a minimum, suppliers will be required to submit the following information in a specified format and via a mechanism defined by the National Department of Health:
 - All transactional data relating to orders;
 - A monthly age analysis;
 - Production pipeline data and forecast including:
 - Number of units of the item available (stock on hand);
 - Number of units of the item in Quality Assurance, awaiting release;
 - Number of units of the item in the current month's production plan.
 - Status of outstanding orders.
- **Attendance of compulsory quarterly meetings**
 - The National Department of Health will hold quarterly meetings with suppliers which will include, but not be limited to, a review of supplier performance and forecasted demand for the next quarter. Suppliers may be required to present continuous improvement initiatives aimed at improving efficiencies in the supply chain to benefit both suppliers and the Department of Health.
- The Participating Authorities shall impose penalties, where deemed necessary, as per Paragraph 21 and 22 of the General Conditions of Contract.
- Non-compliance of contracted suppliers to the terms and conditions of this contract may influence participation in future contracts.



-
- Contractors should note that each individual purchasing institution is responsible for generating the order(s) as well as for the payment(s) thereof.
 - Contractors should note that the order(s) will be placed as and when required during the contract period and delivery points will be specified by the relevant purchasing institution(s).
 - The instructions appearing on the official order form regarding the supply, dispatch and submission of invoices must be strictly adhered to and under no circumstances should the contractor deviate from the orders issued by the purchasing institutions.
 - The Department of Health is under no obligation to accept any quantity which is in excess of the ordered quantity.
 - In order to facilitate efficient implementation of the direct delivery strategy, contracted suppliers must pack orders for the health establishment as per the purchase order.
 - Only orders made using an official, authorised purchase order format are valid.
 - Suppliers are required to acknowledge receipt of all purchase orders received from Participating Authorities, in a manner stipulated by the relevant Participating Authority.
 - Changes to any quantities ordered may only be made upon receipt of an amended purchase order.
 - The Participating Authorities reserve the right to cancel orders where the lead time exceeds the delivery lead time specified in the contract and may, at their discretion, purchase supplies of a similar quality and up to the same quantity in substitution of the goods not supplied in conformity with the contract (as per paragraph 21.6 of the General Conditions of Contract).
 - In cases where an order is received which appears to be irrational or misaligned with estimates, the contracted supplier must liaise with the relevant Participating Authority prior to processing the order.

26.2 DELIVERY ADHERENCE

- Products and related documentation must be delivered in accordance with the terms, conditions and delivery instructions stipulated on the purchase order.
- The information on invoices and documents relating to delivery must comply with the minimum data requirements as defined by the National Department of Health.
- Invoices must reflect both the "proprietary name "(brand name"/"trade name") which is unique to a particular medicine, and which is the name approved in terms of section 15(4) of the Medicines and Related Substances Act, 1965 (Act 101 of 1965), and the item description as it appears in the contract circular and Master Procurement Catalogue (MPC), or Master Health Product List (MHPL), which will replace the MPC.



-
- Original invoices and proof of delivery must be authorised by a delegated official at the designated delivery point. These documents must be delivered to the authority responsible for payment. This may or may not be the same as the delivery address stipulated on the purchase order. Suppliers are required to know where documents must be delivered.
 - The supplier must ensure that products are delivered in accordance with the appropriate conditions of storage, as per product's conditions of registration. Delivery is deemed to terminate upon signature of receipt by the delegated official.
 - Discrepancies between invoice and physical stock, or damaged stock, will be reported to the contracted supplier within a reasonable time or as arranged with the supplier. This time period must make provision for the quantities received to be checked upon receipt of delivery.
 - Contracted suppliers will be responsible for collection of goods delivered erroneously, or in the incorrect condition as formally arranged in consultation with the purchasing authority. The Participating Authorities may recoup any expenses associated with failure to collect such goods in accordance with the agreement

26.3 CONTINUITY OF SUPPLY

- Contracted suppliers must have at least two months' supply of the estimate at the start of the contract.
- Contractors must maintain sufficient buffer stock throughout the duration of the contract.
- Contractors must inform National Department of Health at first knowledge of any circumstances that may result in interrupted supply, including but not limited to:
 - regulatory action which may impact on their GMP status or that of entities on which they are reliant;
 - any anticipated problems associated with the availability of active pharmaceutical ingredient (API);
 - industrial action
 - challenges with manufacturing pipeline;
 - any other supply challenges.
- Contractors must direct official communication relating to continuity of supply to stockalert@health.gov.za, as well as Participating Authorities.
- Contractors must direct official communication relating to payment challenges to medacc@health.gov.za, as well as Participating Authorities.
- All official communication must include detail of corrective actions taken by the contracted supplier to ensure continuity of supply.



-
- It is the responsibility of the contracted supplier to ensure continuous availability and supply of contracted items. In the event that the contracted supplier is unable to supply, the contracted supplier is required to source alternative product of acceptable quality and up to the same quantity as required for a period of not more than three months. In the case of a multiple award, the alternative product should not be sourced from another contracted supplier for the same product.
 - In the event that a contracted supplier is unable to supply in the short term, the National Department of Health reserves the right to proportionally reallocate volumes to an alternative contracted supplier for the duration of the contracted supplier's inability to supply.
 - Prior to the supply of an alternative product can be undertaken, the contracted supplier is required to submit the samples of the product to be supplied to the two health establishments as listed in section 4. The contracted supplier is also required to furnish the Department of Health with the following information:
 - Name of the product to be supplied;
 - The quantities to be supplied; and
 - The period for which the product will be supplied.
 - The alternative product must be supplied at the current price of the contracted item.
 - This provision is only applicable for emergency supply and cannot be used for routine and continuous supply of the product.
 - Suppliers may be required to pay penalties for supply exceeding the contractual lead time as stipulated in the General Conditions of Contract Paragraph 22.
 - In terms of the General Conditions of Contract and Special Requirements and Conditions of Contract, the Participating Authorities may purchase outside the contract in order to meet its requirements if the item is urgently required and is not immediately available.

26.4 REPORTING

National Department of Health will provide the requirements for reporting and successful bidders will be assisted with complying with these requirements.

The National Department of Health may, from time to time and within reason, add to the reporting requirements. Any changes to reporting requirements or the reporting mechanism will be communicated in writing by the Directorate: Affordable Medicines.



27. PACKAGING, LABELLING AND BARCODES

27.1 PACKAGING

- Suppliers must ensure that products delivered are received in good order at the point of delivery. Packaging must be suitable for further dispatch, storage and stacking according to Good Wholesaling Practice and Good Distribution Practice.
- Packaging must be suitable for transportation and should prevent exposure to conditions that could adversely affect the stability and integrity of the product.
- The packaging must be uniform for the duration of the contract period. All products must be packaged in acceptable containers, specifically developed for the product.
- The number of units per shipper pack or original carton must be completed in the Bid Response Document.
- Where a particular stacking and storage configuration is recommended by the supplier, this should be clearly illustrated on the outer packaging.
- Where the contents of the shipper pack represent a standard supply quantity of an item, the following must be adhered to:
 - Outer packaging flanges must be sealed with suitable tape that will clearly display evidence of tampering;.
 - The contents must be packed in neat, uniform rows and columns that will facilitate easy counting when opened.
 - Where the contents of a shipper pack represent a non-standard supply quantity, the following must be adhered to:
 - Outer packaging flanges must be sealed with suitable tape that will clearly display evidence of tampering;.
 - The shipper pack must contain only one product, mixing of multiple products in a single shipper is not allowed;.
 - The outer packaging must be clearly marked as a "Part Box".

27.2 LABELLING

- All containers, packaging and cartons must be clearly labelled. Bulk packs must be labelled in letters not less than font size 48.



- The following information must be clearly and indelibly printed on all shipper packs, including any part boxes:
 - Item name as contained in the contract circular and the Master Procurement Catalogue (MPC), or Master Health Products List (MHPL), which will replace the MPC.
 - Registered product name (if applicable);
 - Number of units in pack
 - Batch number;
 - Expiry date;
 - Storage conditions;
 - Barcode.
- Where the contents of the shipper pack require special attention in terms of storage and/or handling, e.g. thermolabile, high-scheduled or cytotoxic products, such instructions must be clearly and visibly indicated on the outer packaging on a brightly coloured background.
- Unit packs must be labelled in accordance with Regulation 10 of the General Regulations published in terms of the Medicines and Related Substances Act, 1965 (Act 101 of 1965). The label must include a barcode suitable for the identification and tracking of medication.

27.3 BARCODES

- All unit and shipper packs must be marked with the appropriate barcode number and symbology.
- The European Article Numbering Code 13 (EAN 13) has been accepted as standard.
- Suppliers are encouraged to include a 2D barcode or similar on their packaging that will include the following information:
 - Item name as contained in the contract circular and the Master Procurement Catalogue (MPC), or Master Health Products List (MHPL) which will replace the MPC.
 - The "proprietary name (brand name"/"trade name") unique to a particular medicine, as approved by MCC or SAHPRA;
 - Dosage form and strength;
 - Pack size;
 - Batch number;
 - Expiry date.



28 SHELF LIFE

- Unless MCC or SAHPRA, has approved a shorter shelf life, products must have a shelf-life of at least 12 months upon delivery.
- Contracted suppliers may apply in writing to Participating Authorities to supply a product with a shorter shelf life provided that:
 - Applications are accompanied by an undertaking that such short-dated products will be unconditionally replaced or credited before or after expiry; and
 - Applications are approved by the Participating Authorities before execution of orders; and
 - Upon notification of remaining expired stock such products will be collected by the supplier at their own cost; and
 - Failure to collect the products within 30 days after written notification to the supplier will result in the disposal of the product by the Participating Authority for the account of the supplier.
- If short-dated products are delivered without the aforementioned undertaking the following discount formula will be applied for invoicing of short-dated products:
 - $A = (12 - \text{months to date of expiry}) \times 2\% \times \text{consignment value short dated product}$. Therefore, amount to be invoiced is: Consignment value minus A, where A is the value of the outcome of the discount formula.
- Unless otherwise agreed to, any Participating Authority may, without prejudice, decline to accept product with a shelf-life of less than 12 months.

29. CEDING, MERGERS, TAKE OVERS AND CHANGES IN SUPPLIER DETAILS

Where a contracted supplier plans to merge with, or is going to be acquired by, another entity or plans to cede a contract the contracted supplier must inform the National Department of Health in writing at first knowledge of such an event.

Where a contracted supplier plans to cede a contracted item to another supplier, the contracted supplier must submit an official request in writing to the NDOH, three months prior to the proposed effective date.

The NDOH reserves the right to accept or decline the request to cede the contractual obligations to the new supplier under the prevailing conditions of contract or to cancel the contract.



The contracted supplier is obliged to supply the contracted item under the prevailing conditions of contract, until such time that the NDOH has approved the request to cede the item to another supplier.

The contracted supplier must inform the National Department of Health at first knowledge of any changes to address, name, or contact details and effect these changes on the Central Supplier Database.

30. CANCELLATION OF THE CONTRACT

Cancellation of a contract will only be considered after compelling evidence to support the request has been submitted to the satisfaction of the Department of Health.

The contracted supplier is obliged to supply the contracted item under the prevailing conditions of contract, until such time that the NDOH has approved the request to cancel the item.

31. THIRD PARTIES

Participating Authorities will not make a payment to or consult with a third party.

No third party is entitled to put an account of a Participating Authority on hold.

END